Liquid botulinum toxin formulations and uses thereof
The formulation stability and photosensitive problems are solved by removing iron ions and tryptophan in the botulinum toxin liquid formulation, combined with dialysis and buffer treatment, and a safer and more stable formulation form is achieved.
Patent Information
- Application Number
- CN202380033828.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-07-05
- Filing Date
- 2023-02-14
- Publication Date
- 2024-11-26
AI Technical Summary
The existing botulinum toxin liquid preparations have poor stability during storage and transportation, are susceptible to photodamage, and contain components such as iron ions and tryptophan, which will affect their light stability, resulting in reduced activity, and may cause pain during injection.
By contacting human serum albumin with chelating agent, a liquid preparation with low iron ions and tryptophan is prepared, and HSA is purified by dialysis and other methods, combined with appropriate buffer and tonic agent to form an optimization The liquid preparation reduces the presence of iron ions and improves light stability.
The excellent stability and safety of the Botox liquid preparation is achieved, which reduces injection pain, simplifies the transportation and storage process, and improves the light stability of the preparation.
Smart Images

Figure BDA0005080793060000351 
Figure BDA0005080793060000352 
Figure BDA0005080793060000371
Abstract
Description
Technical Field
[0001] The present invention relates to a liquid formulation comprising (i) botulinum toxin, (ii) human serum albumin (HSA), and optionally (iii) a tonicity agent and / or (iv) a buffer. The liquid formulation is characterized in that the iron concentration is very low and / or tryptophan and / or N-acetyl-tryptophan are absent or in very low concentration. The present invention also relates to a liquid formulation prepared by a method comprising the steps of contacting human serum albumin with a chelating agent to obtain a mixture, and removing the chelating agent from the mixture. In addition, the present invention relates to the use of the liquid formulation in the treatment of therapeutic indications and cosmetic conditions. Background Art
[0002] Botulinum neurotoxins (BoNT or botulinum toxin (BT)) are a family of bacterial neurotoxins that are widely used to treat a growing number of neurological, medical and cosmetic conditions. There are eight widely accepted "classical" BoNT serotypes, designated BoNT / AH. There are currently two serotypes in clinical use, type A (BoNT / A) and type B (BoNT / B). BoNTs are produced by Clostridium spp., particularly Clostridium botulinum, in the form of high molecular weight (up to ~900 kDa) complexes. These toxin complexes consist of an active 150 kDa neurotoxin and a variety of complexing proteins (non-toxic neurotoxin-associated proteins, NAPs).
[0003] The 150 kDa neurotoxin is synthesized as an inactive single-chain polypeptide (~150 kDa) that is proteolytically cleaved into a light chain (LC, ~50 kDa) and a heavy chain (HC, 100 kDa) linked by interchain disulfide bonds. The HC contains a C-terminal domain that mediates binding to the receptor and an N-terminal domain that mediates translocation of the LC across the endosomal membrane. The LC acts as a protease in neurons and cleaves neuronal SNARE proteins. This prevents the fusion of synaptic vesicles with the plasma membrane, thereby inhibiting the release of neurotransmitters from selected neurons.
[0004] The formulation of BoNT is very challenging due to its complex structure and the low concentrations of the products used. BoNT is extremely susceptible to various conditions, such as heat and alkaline pH. Therefore, since BoNT is only functional when its structure is intact, the challenge in preparing a medical dosage form of BoNT is to formulate a composition that protects the BoNT from inactivation or partial loss of biological activity during the production, storage or use of the product. Another problem is that pharmaceutical preparations of BoNT contain very small amounts of highly potent toxin (human lethal dose is about 0.1 to 1 ng / kg), only about 1 ng per bottle. This exacerbates the problem of loss of toxin activity due to surface denaturation. In addition, formulations of BoNT are used for a wide range of different applications and therefore must be compatible with injection into very different types of tissues, such as muscle, different skin layers (e.g., dermis, subcutaneous tissue), or glands (e.g., salivary glands).
[0005] In view of the above, the main BoNT products currently available are provided in the form of lyophilized powders, i.e., a form that is stable for a long time when stored at 2-8°C or even at room temperature (e.g. The lyophilized form of the BoNT / A complex was first described in 1989 ( Allergan) and 1991 ( Ipsen) was first marketed. In 2005, the first stable formulation of a pure 150 kDa BoNT / A neurotoxin without complexing proteins was approved ( Merz Pharmaceuticals). However, these lyophilized products need to be reconstituted before use, a process that can lead to dosage errors and sterility issues. Therefore, there have been a lot of efforts to develop liquid formulations of BoNT that are more convenient to use and can be easily administered.
[0006] The first liquid formulation of BoNT was approved in 2000 and in 2001 as Available in Europe. (Eisai) is a sterile solution of BoNT / B complex formulated in a buffer containing disodium succinate, sodium chloride, human serum albumin (HSA), sodium octanoate, and sodium N-acetyl-tryptophan. However, due to its acidic pH, this product may be painful upon injection. For BoNT / A, only two liquid formulations have received market approval to date: (Medytox), but only in domestic Asian markets (e.g., South Korea, approved in 2013), and (lpsen / Galderma), approved for use in Europe in 2021. Both liquid formulations contain the BoNT / A toxin complex and, in addition to water, contain sodium chloride, a detergent ( polysorbate 20; Polysorbate 80), amino acids ( Methionine; Histidine) and additional excipients ( Sodium phosphate as buffer; sucrose).
[0007] Despite these advances in the preparation of liquid botulinum toxin formulations, there remains a need for stable liquid botulinum toxin formulations, and in particular, there remains a need for new options for developing ready-to-use liquid botulinum toxin formulations that are stable during shipping and storage.
[0008] Purpose of the invention
[0009] It is therefore an object of the present invention to provide a stable liquid formulation of botulinum toxin suitable for cosmetic and therapeutic applications. Summary of the invention
[0010] The present invention is based on the surprising discovery that human serum albumin (HSA) pretreated by incubation with a chelating agent such as EDTA followed by removal of the chelating agent enables the preparation of liquid formulations of botulinum toxin that exhibit not only excellent storage stability but also excellent and improved photostability. Furthermore, the present invention is based on the surprising discovery that iron ions, particularly Fe 3+ ions, which have a deleterious effect on the photostability of liquid botulinum toxin formulations containing HSA.
[0011] Furthermore, the present invention is based on the surprising discovery that tryptophan and N-acetyl-tryptophan reduce the photostability of liquid botulinum toxin formulations containing human serum albumin (HSA). This discovery is very surprising because commercially available HSA products, in addition to water and sodium chloride, usually contain sodium octanoate and N-acetyl-tryptophan to stabilize HSA at high temperatures, which in this way enter the botulinum toxin formulation. This is also surprising because tryptophan has been described as a stabilizing additive for botulinum toxin (see, for example, EP 3 679946).
[0012] Therefore, in a first aspect, the present invention provides a liquid preparation comprising:
[0013] (i) Botulinum toxin and
[0014] (ii) human serum albumin (HSA),
[0015] The liquid preparation contains Fe at a concentration of less than 1 μM, preferably less than 500 nM, more preferably less than 250 nM, and most preferably less than 100 nM. 3+ ion.
[0016] With low Fe, for example, less than 1 μM 3+ The liquid botulinum toxin preparation of the concentration can be prepared by a method comprising the steps of: step (a) contacting human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and step (b) removing the chelating agent from the mixture.
[0017] In a second aspect, the present invention provides a liquid preparation comprising:
[0018] (i) Botulinum toxin and
[0019] (ii) human serum albumin (HSA),
[0020] The liquid preparation contains no tryptophan and N-acetyl-tryptophan, or contains tryptophan and N-acetyl-tryptophan (total concentration of Trp and N-AcTrp) of no more than 50 μM, preferably no more than 20 μM, more preferably no more than 10 μM, still more preferably no more than 1 μM, and most preferably 0 μM.
[0021] The liquid formulation according to the first and second aspects of the present invention preferably further comprises (iii) a tonicity agent, in particular sodium chloride, and (iv) a buffer, in particular a histidine buffer, a phosphate buffer or a mixture thereof. A liquid botulinum toxin formulation containing no or only very low concentrations of tryptophan and / or N-acetyl-tryptophan can be prepared by purifying the HSA starting material by a method such as dialysis and using the purified HSA starting material in the preparation of the liquid formulation of the present invention.
[0022] In a third aspect, the present invention provides a liquid preparation comprising:
[0023] (i) Botulinum toxin and
[0024] (ii) human serum albumin (HSA),
[0025] Wherein the human serum albumin is prepared by a method comprising the following steps:
[0026] (a) contacting human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and
[0027] (b) removing the chelating agent from the mixture.
[0028] The contacting step (a) is preferably carried out by adding a chelating agent (e.g., EDTA) to a composition comprising HSA (e.g., a HSA solution) and incubating the resulting mixture for a predetermined time, optionally followed by dialysis against a buffer containing the chelating agent (e.g., EDTA). In step (b), the chelating agent is removed by any suitable method (e.g., by dialysis).
[0029] Furthermore, the liquid formulation according to the third aspect of the present invention preferably further comprises (iii) a tonicity agent, in particular sodium chloride, and / or (vi) a buffer, in particular a histidine buffer, a phosphate buffer or a mixture thereof.
[0030] In a fourth aspect, the present invention relates to a method for preparing a liquid formulation according to the second aspect of the present invention, wherein the method comprises the following steps:
[0031] - purifying the human serum albumin starting material to obtain a purified human serum albumin material, for example by subjecting the human serum albumin starting material to dialysis, diafiltration, ultrafiltration, ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography or field flow fractionation, preferably dialysis,
[0032] - mixing the obtained purified human serum albumin with botulinum toxin and optionally other components to obtain a liquid preparation,
[0033] The alternative method according to the fourth aspect of the present invention comprises the following steps:
[0034] - purifying the liquid composition comprising botulinum toxin and human serum albumin to obtain a purified liquid composition, for example by subjecting the liquid composition comprising botulinum toxin and human serum albumin to dialysis, diafiltration, ultrafiltration, ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography or field flow fractionation, preferably dialysis,
[0035] - The purified liquid composition obtained is mixed with other components to obtain a liquid preparation.
[0036] In a fifth aspect, the present invention relates to a liquid formulation according to the present invention for use in therapy, in particular for use in the treatment of neuromuscular diseases, pain, salivation, hyperhidrosis, urological diseases and nervous system diseases.
[0037] In a sixth aspect, the present invention relates to the cosmetic (aesthetic) use of the liquid formulation of the present invention for treating a cosmetic condition, preferably a skin condition, in particular for treating skin lines or folds or wrinkles.
[0038] In a seventh aspect, the present invention provides a method for treating a disease or condition, comprising administering an effective amount of the liquid formulation of the present invention to a person in need thereof.
[0039] Preferred embodiments of the liquid formulation according to the invention, its use and method of use are set out in the appended claims.
[0040] The present invention may be understood more readily by reference to the following detailed description of the invention and the Examples included therein. DETAILED DESCRIPTION
[0041] The present invention is based on the unexpected discovery that the use of pretreated human serum albumin (HSA) in the formulation of liquid botulinum toxin formulations results in reduced photosensitivity, thereby resulting in improved photostability. In addition, it was unexpectedly found that very small amounts of iron ions (Fe 2+) obtained by chelating agent treatment followed by dialysis 3+ ions) significantly increased the photosensitivity of liquid botulinum toxin formulations containing human serum albumin (HSA). This was surprising because iron is relatively common and ubiquitous, and other metal ions such as copper, cobalt or nickel were found not to show this destabilizing effect.
[0042] Furthermore, the present invention is based on the unexpected discovery that tryptophan and / or N-acetyl-tryptophan impair the photostability (photostability) of liquid botulinum toxin formulations containing human serum albumin (HSA). Specifically, it was found that removal of N-acetyl-tryptophan from conventional HSA products by chelating agent treatment and subsequent dialysis resulted in liquid botulinum toxin formulations containing HSA with improved photostability.
[0043] Compared to freeze-dried botulinum toxin preparations in powder form, the liquid preparations of the present invention advantageously provide improved safety and dosage accuracy because the preparations do not need to be reconstituted before injection, but are ready-to-use and can be used, for example, in the form of pre-filled syringes. In addition, the excellent stability of the liquid preparations facilitates and simplifies transportation and storage and the operation of doctors. In particular, the excellent light stability of the liquid preparations of the present invention simplifies the manufacturing process, allows the product to be filled and packaged without a large amount of light protection, and reduces the potential loss of activity caused by storage under exposure to light at the doctor's place before use. In addition, the liquid preparations of the present invention do not contain substances that cause increased injection pain, thereby increasing the acceptance of the preparations by doctors and patients, particularly in the field of beauty.
[0044] Without being bound by theory, it is believed that the photosensitivity of the formulations of the present invention is related to the presence of substances such as N-acetyl-tryptophan and Fe contained in the HSA used to prepare the liquid botulinum toxin formulation. 3+ However, the exact mechanism by which removal of these substances increases HSA's ability to stabilize botulinum toxin against light remains unclear.
[0045] As used herein, the term "comprising", like the terms "including", "containing", and any variations thereof, such as "comprising", "including" and "containing", is intended to represent a non-exclusive inclusion, such that a process, method, product obtained by a process, composition or preparation that comprises, includes or contains an element or a series of elements includes not only those elements, but may also include other elements not explicitly listed for such process, method, product obtained by a process, composition or preparation. Furthermore, within the framework of the present invention, it is intended that each of the terms "comprising", "including", "containing" and any variations thereof may be replaced by the term "consisting of" or any variations thereof (e.g., "consisting essentially of"), which will be understood to refer to the exclusive inclusion of the indicated elements.
[0046] The terms “a” and “an” and “the” and similar references used in the context of the present invention are to be construed to cover both the singular and the plural, and thus may also refer to “at least one” or “more than one” unless otherwise indicated herein or clearly contradicted by context.
[0047] As used herein, the term "liquid formulation" or "liquid botulinum toxin formulation" generally refers to an aqueous formulation, generally an aqueous solution. In this document, the term "liquid formulation" can be used interchangeably with "liquid composition". The liquid formulation is generally a pharmaceutically acceptable liquid formulation, or in other words, a liquid pharmaceutical formulation. The liquid formulation of the present invention generally has a pH value of 5.0-8.0, particularly 5.5-7.5, preferably 5.5-7.0 or 6.0-7.5, more preferably 6.0-7.0, and most preferably 6.0-6.5.
[0048] The term "pharmaceutically acceptable" as used herein means that the liquid formulation does not cause unacceptable adverse side effects when administered to a human patient or subject. That is, this means that the liquid formulation is suitable for human use. The aqueous solution can be a buffered solution, with or without a saline solution, and can be a physiological saline solution, such as a buffered (e.g., phosphate and / or histidine buffered) physiological saline solution.
[0049] It is contemplated herein that liquid preparations of the present invention can be stored in any suitable container system. Suitable container systems for storing liquid preparations of the present invention are any devices with partially or completely enclosed space, which can be sealed or sealed, and can be used to accommodate, store and / or transport liquid preparations. Container systems are preferably made of glass or plastic (e.g., organic polymers) or partially or mainly made of glass or plastic closure (or sealing) containers, and include containers such as the following forms: (i) syringe, (ii) bottle, (iii) carpule, or (iv) ampoule. In a preferred embodiment of the present invention, as known in the art, liquid preparations are stored in syringes in the form of pre-filled syringes.
[0050] The term "botulinum toxin" as used herein is not particularly limited and includes botulinum toxins of any serotype (BoNT / AG). For example, the botulinum toxin may be serotype A or B (BoNT / A, BoNT / B). Preferably, the botulinum toxin is serotype A, more preferably serotype A1 (BoNT / A1), and most preferably BoNT / A1 produced by the Hall strain of Clostridium botulinum. In addition, the botulinum toxin may be a natural neurotoxin obtainable from the bacterium Clostridium botulinum or any other botulinum toxin, such as a botulinum toxin obtainable from alternative sources, including recombinant technology and genetic or chemical modification.
[0051] Furthermore, as used herein, the term "botulinum toxin" ("BT") and the synonymous term "botulinum neurotoxin" ("BoNT") refer to pure botulinum neurotoxin and / or any complex thereof, i.e. any complex of pure botulinum neurotoxin and a complexing protein (referred to as "toxin complex"), unless otherwise specified or the context indicates otherwise. Preferably, within the framework of the present invention, the botulinum toxin is a botulinum neurotoxin free of a complexing protein, more preferably a botulinum neurotoxin free of a complexing protein of serotype A.
[0052] As used herein, the term "pure botulinum neurotoxin" refers to a botulinum neurotoxin without complexing proteins (sometimes also referred to as a "neurotoxic component"), or more precisely, to a botulinum neurotoxin without neurotoxin-associated complexing proteins (NAPs). Pure botulinum neurotoxin is an (active) neurotoxic polypeptide that ultimately inhibits the release of acetylcholine. It is a two-chain protein comprising a light chain (LC; about 50 kDa) and a heavy chain (HC; about 100 kDa) bound together by disulfide bonds. Therefore, the active neurotoxic polypeptide may also be referred to herein as a "150 kDa neurotoxin," "botulinum neurotoxin (150 kD)," or a "neurotoxic component."
[0053] The term "toxin complex" as used herein refers to a high molecular weight complex of the neurotoxic component and a group of complexing proteins (NAPs). In particular, the term "toxin complex" includes 900 kDa, 500 kDa and 300 kDa botulinum toxin type A complexes. The complexing proteins are non-toxic non-hemagglutinins (NTNHA) and different hemagglutinins (HA) in AD serotype strains. For example, the 900 kDa complex is contained in onabotulinumtoxin A ( Allergan, Inc., Irvine, CA, USA). In addition, ( Ipsen, Paris, France), (lpsen / Galderma) and (Medytox) contains a toxin complex as an active agent. That is, it contains and The toxin complex in the liquid preparation of the present invention is a toxin complex in the sense of the present invention and is therefore a "botulinum toxin" according to the present invention. According to the present invention, the botulinum toxin may be present in the liquid preparation of the present invention in the range of 1-1000 U / ml, preferably in the range of 10-200 U / ml, more preferably in the range of 20-150 U / ml, and most preferably in the range of 50 U / ml-100 U / ml.
[0054] The term "unit" or "U" as used herein refers to the biological activity (biopotency) of a toxin and is related to the dose that is lethal to 50% of the mice tested (LD 50 More specifically, in the context of the present invention, unless otherwise specified, LD 50 The MBA determines the mean lethal dose (LD) of toxins / neurotoxins after intraperitoneal injection in mice. 50 ), i.e., the dose of toxin / neurotoxin that kills 50% of a group of mice. On this basis, as used herein, 1 unit (U) of toxin / neurotoxin is defined as one mouse LD 50 (1.0LD 50 =1.0U).
[0055] LD 50 Mouse bioassay is the gold standard among various biological, chemical or immunological detection methods of botulinum toxin and is known to those skilled in the art (see, e.g., Pearce, LB; Borodic, GE; First, ER; MacCallum, RD Measurement of botulinum toxin activity: Evaluation of thelethality assay. Toxicol. Appl. Pharmacol. 1994, 128: 69-77). Those skilled in the art will be able to determine the appropriate botulinum toxin concentration based on the serotype and intended use. Alternatively, cell-based assays may be used to determine botulinum toxin activity, such as described in WO 2009 / 114748, WO 2013 / 049508 or WO 2014 / 207109. Those skilled in the art will be able to determine the appropriate botulinum toxin concentration by using LD 50 Botulinum toxin activity results obtained from cell-based assays were compared to mouse LD 50 The results obtained were correlated with the assay.
[0056] Since manufacturers of commercial botulinum toxin preparations use LD 50 Assays vary, and the unit potency stated by manufacturers for their commercial botulinum toxin preparations is proprietary and not easily comparable. Therefore, within the framework of the present invention, the conversion ratios provided below are used to establish incobotulinumtoxinA ("INCO"; Botulinum toxin serotype A, without complexing protein; Merz Pharmaceuticals GmbH), onabotulinumtoxinA ("ONA"; Botulinum toxin complex of serotype A; Allergan Inc.), abobotulinumtoxinA (“ABO”; Botulinum toxin complex of serotype A; Medicis Pharmaceutical Corp., Galderma Lab.), rimabotulinumtoxinB ("RIM"; Botulinum toxin serotype B; Solstice Neurosciences Inc.) and ("TBD"; botulinum toxin serotype A; Mentor Worldwide LLC). Herein, the conversion ratio of ONA and INCO is 1:1. The conversion ratio of ONA / INCO:ABO is 1:2.5. The conversion ratio of ONA / INCO:RIM is 1:50, and the conversion ratio of ONA / INCO:TBD is 1:1. In addition, within the scope of the present invention, 1 U of INCO and 1U of onabotulinumtoxinA (“ONA”; ) should be considered to correspond to one mouse LD50 (1.0 LD50), or 1 U, as measured above.
[0057] As used herein, the term "human serum albumin" or its abbreviation "HSA" refers to donor HSA (HSA derived from human blood, or more precisely, HSA derived from human plasma) and recombinant HSA. Preferably, human serum albumin is donor HSA. In the present invention, human serum albumin (HSA) serves as a stabilizing protein. As used herein, the term "stabilizing protein" generally refers to a polypeptide that causes increased stability of botulinum toxin. According to the present invention, HSA may be present in the liquid preparation in an amount of 0.001-2.0% w / v, preferably in an amount of 0.001-1.00% w / v, more preferably in an amount of 0.01-0.5% w / v, still more preferably in an amount of 0.02-0.3% w / v, and most preferably in an amount of 0.03-0.15% w / v.
[0058] In a first aspect, the present invention relates to a liquid preparation comprising:
[0059] (i) Botulinum toxin and
[0060] (ii) human serum albumin,
[0061] The liquid formulation contains Fe at a concentration of less than 1 μM 3+ ion
[0062] Preferably, Fe in the liquid formulation 3+ The concentration is less than 1000 nM, less than 750 nM, less than 500 nM or less than 250 nM. More preferably, the Fe 3+ The concentration is less than 200 nM, less than 150 nM or less than 100 nM. It is particularly preferred that the Fe 3+ The concentration is less than 50 nM or less than 10 nM, most preferably, the Fe in the liquid formulation 3+ The concentration is less than 1 nM, less than 100 pM, less than 10 pM, or less than 1 pM.
[0063] Metal ions (such as Ca 2+ 、Co 2+ , Cu 2+ 、Ni 2+ or Fe 3+ ) can be determined by measurement methods known to those skilled in the art, such as atomic absorption spectroscopy (AAS), inductively coupled plasma mass spectrometry (ICP-MS) and inductively coupled plasma atomic emission spectroscopy (ICP-AES) (also known as inductively coupled plasma optical emission spectroscopy (ICP-OES)). Preferably, ICP-MS or ICP-OES, in particular ICP-OES, can be used to measure the concentration of metal ions (see also Second Supplement to USP38-NF 33, Chemical Tests / <233> Elemental Impurities–Procedure 1 (ICP-OES) and Procedure 2 (ICP-MS), 2015).
[0064] Without being bound by theory, it is believed that the HSA material used to prepare the liquid formulation of the present invention, especially the donor HSA from human blood containing a large amount of iron ions, contains a large amount of Fe 3+ ions, which is responsible—at least in part—for the photosensitizing properties of unpurified (untreated) HSA.
[0065] In addition to the above advantages, this aspect of the invention is also advantageous in the development of manufacturing processes and new formulations. For example, equipment (e.g., containers) and materials (e.g., excipients) can be selected so that as little iron as possible is present in the final product.
[0066] With low Fe 3+ The liquid botulinum toxin preparation of the present invention having a concentration of 100 μg / ml can be prepared by a method comprising the steps of (a) contacting human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and (b) removing the chelating agent from the mixture.
[0067] Preferably, the method for preparing the liquid preparation according to the first aspect of the present invention is identical with the method described in conjunction with the third aspect of the present invention. In addition, the liquid preparation according to the first aspect of the present invention can have the same composition as the liquid preparation according to the third aspect of the present invention. Therefore, unless otherwise clearly stated, all explanations, comments, disclosures, definitions, etc. given to the liquid preparation according to the third aspect of the present invention are equally applicable to the liquid preparation according to the first aspect of the present invention.
[0068] In a second aspect, the present invention relates to a liquid preparation comprising:
[0069] (i) Botulinum toxin and
[0070] (ii) human serum albumin, wherein the liquid preparation contains no or no more than 50 μM tryptophan and N-acetyl-tryptophan.
[0071] The term "free" of tryptophan and N-acetyl-tryptophan as used herein means that the liquid formulation does not contain or is completely free of tryptophan and N-acetyl-tryptophan. Specifically, this means that the formulation does not contain added tryptophan and N-acetyl-tryptophan. Alternatively, this means that the concentration of tryptophan and N-acetyl-tryptophan in the liquid formulation is 0 μM (i.e., <0.5 μM according to the general rule of rounding), in particular £0.1 μM or £0.01 μM or £0.001 μM, more particularly 0 nM (i.e., <0.5 nM according to the general rule of rounding). As used herein, the term "containing no more than ..." tryptophan and N-acetyl-tryptophan means that the total amount of tryptophan and N-acetyl-tryptophan can be £50μM, preferably £20μM, more preferably £10μM, still more preferably £1μM, still more preferably £0.1μM, most preferably £0.01μM or £0.001μM. Therefore, as used herein, the term "does not contain or contains no more than ..." means that the total amount of tryptophan and N-acetyl-tryptophan in the liquid preparation is between 0μM and X or between 0nM and X, wherein X is 50μM, 20μM, 10μM, 1μM, 0.1μM, 0.01μM and 0.001μM.
[0072] The concentration of amino acids tryptophan and N-acetyl-tryptophan can be determined by various techniques (e.g., DC, HPLC, LC-MS, GC-MS, CE, etc.). For example, N-acetyl-tryptophan can be determined by separation using liquid chromatography on a reverse phase column as described by Nelis et al. (Nelis et al., J. Chromatogr., 1985, 333 (2): 381-387) and UV detection at 280 nm, or by a method based on ultraviolet spectrophotometry of the acid-soluble portion remaining after protein precipitation as described by Yu and Finlayson (Yu, MW and Finlayson, JS, J. Pharm. Sci., 1984, 73 (1): 82-86). Tryptophan can be quantitatively determined, for example, using a method involving liquid chromatography-tandem mass spectrometry as described by Wentao et al. (Wentao et al., Analytical and Bioanalytical Chemistry, 2011, 401: 3249-3261).
[0073] The term "tryptophan" as used herein refers to L-tryptophan, D-tryptophan, or a mixture of L-tryptophan and D-tryptophan (D / L-tryptophan). Likewise, the term "N-acetyl-tryptophan" as used herein refers to N-acetyl-L-tryptophan, N-acetyl-D-tryptophan, or a mixture of N-acetyl-L-tryptophan and N-acetyl-D-tryptophan (N-acetyl-D / L-tryptophan).
[0074] The human serum albumin used for preparing the liquid preparation is preferably a human serum albumin material containing not more than 50 mM, more preferably not more than 20 mM or 10 mM, still more preferably not more than 1 mM or 0.1 mM, most preferably not more than 0.01 nM or 0 mM tryptophan and N-acetyl-tryptophan.
[0075] It is reported that commercially available HSA products contain a large amount of N-acetyl-tryptophan (>10mM). Therefore, before being used to prepare the liquid preparation of the present invention, these products need to be purified to reduce the amount of N-acetyl-tryptophan to the desired level. A suitable method for preparing "purified HSA" is described in detail below in conjunction with the fourth aspect of the present invention. In short, human serum albumin containing no or a small amount of tryptophan and N-acetyl-tryptophan (also referred to herein as "purified HSA") can be obtained by dialyzing, diafiltration, ultrafiltration, ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, field flow fractionation or precipitation (e.g., salt precipitation, ethanol precipitation) of the human serum albumin starting material to remove tryptophan and / or N-acetyl-tryptophan.
[0076] According to the present invention, the liquid formulation of the present invention, for example the liquid formulation according to the first, second and / or third aspect of the present invention, may further comprise one or both of (iii) a tonicity agent and (iv) a buffer as described in more detail below, in particular in relation to the liquid formulation according to the third aspect of the present invention.
[0077] Furthermore, it is contemplated herein that the liquid formulation according to the second aspect of the present invention preferably comprises Fe at a concentration of less than 1000 nM. 3+ ions. Specifically, Fe 3+ The concentration is preferably less than 750 nM, less than 500 nM or less than 250 nM. More preferably, the Fe 3+ The concentration is less than 200 nM, less than 150 nM or less than 100 nM. It is particularly preferred that the Fe 3+ The concentration is less than 50 nM or less than 10 nM, most preferably, the Fe in the liquid formulation 3+ The concentration is less than 1 nM, less than 100 pM, less than 10 pM, or less than 1 pM.
[0078] As mentioned above, it was also found that Fe 3+ The Fe ions reduce the photostability of botulinum toxin, thereby increasing the destabilization of tryptophan and N-acetyl-tryptophan. It is believed that the HSA material used to prepare the liquid formulation of the present invention, especially the donor HSA from human blood, contains a large amount of Fe 3+ ions, which leads to reduced photostability of unpurified (untreated) HSA. 3+ The concentration, equipment (eg container) and materials (eg excipients) should be chosen so that as little iron as possible is present in the final product, for example by choosing a container made of an iron-free material such as polypropylene or polycarbonate.
[0079] Metal ions (e.g., Fe 3+ and Ca 2+ 、Co 2+ , Cu 2+ 、Ni 2+ The concentration of ) can be determined by measurement methods known to those skilled in the art and disclosed above.
[0080] The low Fe content of the liquid botulinum toxin formulation of the present invention 3+ The content may be achieved by the method described in detail in conjunction with the fourth aspect of the invention, in particular by a method comprising contacting human serum albumin with a chelating agent and then removing the chelating agent as described herein.
[0081] According to the present invention, unless otherwise specified or intended, the liquid preparation may also include one or more other pharmaceutically acceptable excipients. For example, the liquid preparation may include one or more of glycerol, sucrose, lactose, mannitol, dextran, hyaluronic acid, polyvinylpyrrolidone, lactic acid, citric acid, amino acids (except tryptophan and N-acetyl-tryptophan), benzyl alcohol, lidocaine, gelatin, hydroxyethyl starch (HES), polyethylene oxide and polysorbate (for example, polysorbate 20 and polysorbate 80). Other suitable pharmaceutically acceptable excipients include those well known in the art, referring to, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania.
[0082] However, it is also contemplated herein that the liquid formulations of the present invention specifically lack certain components (i.e., compounds, materials, or substances), such as chelating agents and / or phosphates, detergents, polysaccharides, amino acids, stabilizing peptides, and the like, including any combination thereof. As used herein, the term "detergent" is synonymous with "surfactant" and is intended to include nonionic and ionic detergents. The term "stabilizing peptide" used herein generally refers to a peptide consisting of 5 to 50 amino acids, such as 10 to 40 amino acids or 15 to 30 amino acids. Therefore, the term "stabilizing peptide" does not include HSA.
[0083] In one embodiment, the liquid preparation of the present invention does not contain detergent, particularly does not contain polysorbate, more particularly does not contain polysorbate 20 and / or polysorbate 80. In another embodiment, the liquid preparation of the present invention does not contain alginate. In another embodiment, the liquid preparation of the present invention does not contain succinate. In another embodiment, the liquid preparation of the present invention does not contain one or more (e.g., 2, 3, 4 or 5 kinds) of amino acids selected from the group consisting of arginine, glutamic acid, methionine, tryptophan and serine. In another embodiment, the liquid preparation of the present invention does not contain carbohydrates, such as monosaccharides, oligosaccharides or polysaccharides or mixtures thereof. In particular, the liquid preparation of the present invention may not include one or more (e.g., 2, 3 or 4 kinds) of sucrose, lactose, maltose and trehalose. In another embodiment, the liquid preparation of the present invention does not contain chelating agents, particularly those described herein in conjunction with the present invention, and / or phosphates. It is also contemplated in the present invention that the liquid preparation lacks more than one or all of the above compounds.
[0084] In one embodiment, the liquid formulation of the present invention lacks (i) detergents and monosaccharides, oligosaccharides and polysaccharides, (ii) detergents and any amino acids, or detergents and all amino acids except histidine, (iii) detergents and stabilizing peptides, (iv) monosaccharides, oligosaccharides and polysaccharides and any amino acids, or monosaccharides, oligosaccharides and polysaccharides and all amino acids except histidine, (v) monosaccharides, oligosaccharides and polysaccharides and stabilizing peptides, (vi) any amino acids and stabilizing peptides, or all amino acids except histidine and stabilizing peptides, (vii) detergents, monosaccharides, oligosaccharides and polysaccharides and any amino acids, or detergents, monosaccharides, Oligosaccharides and polysaccharides and all amino acids except histidine, (viii) detergents, monosaccharides, oligosaccharides and polysaccharides, and stable peptides, (ix) detergents, any amino acids, and stable peptides, or detergents, all amino acids except histidine, and stable peptides, (x) monosaccharides, oligosaccharides and polysaccharides, any amino acids, and stable peptides, or monosaccharides, oligosaccharides and polysaccharides, all amino acids except histidine, and stable peptides, (xi) detergents, monosaccharides, oligosaccharides and polysaccharides, any amino acids and stable peptides, or detergents, monosaccharides, oligosaccharides and polysaccharides, all amino acids except histidine, and stable peptides.
[0085] In another embodiment, the liquid formulation of the present invention does not contain any other amino acids except histidine. In another embodiment, the liquid formulation of the present invention does not contain any monosaccharides, disaccharides and trisaccharides. In another embodiment, the liquid formulation of the present invention does not contain any other stabilizing peptides or proteins except HSA. In another embodiment, the liquid formulation of the present invention does not contain phosphates, such as phosphates in the form of phosphate buffers.
[0086] In other embodiments, the liquid formulations of the invention lack (i) succinate and a detergent (e.g., polysorbate), (ii) succinate and methionine, (iii) succinate and sucrose, (iv) a detergent (e.g., polysorbate) and methionine, (v) a detergent (e.g., polysorbate) and sucrose, (vi) methionine and sucrose, (vii) succinate, a detergent (e.g., polysorbate) and methionine, (vii) succinate, a detergent (e.g., polysorbate) and methionine, ( xiii) succinate, a detergent (e.g., polysorbate) and sucrose, (ix) succinate, methionine and sucrose, (x) a detergent (e.g., polysorbate), methionine and sucrose, and (xi) succinate, a detergent (e.g., polysorbate), methionine and sucrose, (xii) a detergent (e.g., polysorbate) and histidine, (xiii) a detergent (e.g., polysorbate), histidine and sucrose).
[0087] Furthermore, any liquid formulation of the invention lacking one or more components (ie, compounds, materials or substances) may also lack a chelating agent, particularly a chelating agent as described herein (eg, EDTA), and / or a phosphate.
[0088] In addition, the preferred liquid formulation of the present invention comprises (i) botulinum toxin, (ii) HSA, (iii) a tonicity agent, and does not contain or contains no more than 50 μM tryptophan and N-acetyl-tryptophan. The preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10 U / ml to 200 U / ml, (ii) 0.01% w / v to 1.0% w / v HSA, (iii) 0.01% w / v to 2.0% w / v tonicity agent, preferably sodium chloride, and does not contain or contains no more than 50 μM tryptophan and N-acetyl-tryptophan. The preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10 U / ml to 200 U / ml, (ii) 0.01% w / v to 0.5% w / v HSA, (iii) 0.1% w / v to 1.5% w / v tonicity agent, preferably sodium chloride, and does not contain or contains no more than 50 μM tryptophan and N-acetyl-tryptophan. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin concentration of 10 U / ml to 200 U / ml, (ii) 0.05% w / v to 0.25% w / v HSA, (iii) 0.6% w / v to 1.2% w / v tonicity agent, preferably sodium chloride, and no or no more than 50 μM tryptophan and N-acetyl-tryptophan. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin concentration of 10 U / ml to 200 U / ml, (ii) 0.01% w / v to 0.5% w / v HSA, (iii) 0.9% w / v sodium chloride as a tonicity agent, and no or no more than 50 μM tryptophan and N-acetyl-tryptophan. A preferred liquid formulation of the present invention comprises (i) botulinum toxin at a concentration of 10 U / ml to 200 U / ml, (ii) 0.05% w / v to 0.25% w / v HSA, (iii) 0.9% w / v sodium chloride as a tonicity agent, and contains no or no more than 50 μM tryptophan and N-acetyl-tryptophan.
[0089] It is also contemplated herein that in the preferred and particularly preferred liquid formulations described in the preceding and following paragraphs, the upper limit of the concentration of tryptophan and N-acetyl-tryptophan is less than 50 μM, preferably 10 μM, more preferably 1 μM, still more preferably 0.1 μM, most preferably 0.01 μM or 0.001 μM. In addition, it is also contemplated herein that the preferred and particularly preferred liquid formulations described in the preceding and following paragraphs may be characterized in that Fe 3+ The concentration of the ions is less than 1000 nM or less than 500 nM, more preferably less than 250 nM or less than 100 nM, most preferably less than 10 nM or less than 1 nM.
[0090] Preferred liquid formulations of the present invention comprise (i) botulinum toxin, (ii) HSA, (iii) a tonicity agent, (iv) a buffer, and contain no or no more than 50 μM tryptophan and N-acetyl-tryptophan. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin concentration of 10 U / ml to 200 U / ml, (ii) 0.01% w / v to 1.0% w / v HSA, (iii) 0.01% w / v to 2.0% w / v tonicity agent, preferably sodium chloride, (iv) a buffer concentration of 1 mM to 100 mM, and contain no or no more than 50 μM tryptophan and N-acetyl-tryptophan. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin concentration of 10 U / ml to 200 U / ml, (ii) 0.01% w / v to 0.5% w / v HSA, (iii) 0.01% w / v to 2.0% w / v tonicity agent, preferably sodium chloride, (iv) a buffer concentration of 1 mM to 100 mM, and no or no more than 50 μM tryptophan and N-acetyl-tryptophan. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin concentration of 10 U / ml to 200 U / ml, (ii) 0.05% w / v to 0.25% w / v HSA, (iii) 0.1% w / v tonicity agent, preferably sodium chloride, (iv) a buffer concentration of 1 mM to 100 mM, and no or no more than 50 μM tryptophan and N-acetyl-tryptophan. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin concentration of 10 U / ml to 200 U / ml, (ii) 0.05% w / v to 0.25% w / v HSA, (iii) 0.6% w / v to 1.3% w / v tonicity agent, preferably sodium chloride, (iv) a buffer concentration of 2 mM to 50 mM, and no or no more than 50 μM tryptophan and N-acetyl-tryptophan. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin concentration of 10 U / ml to 200 U / ml, (ii) 0.05% w / v to 0.25% w / v HSA, (iii) 0.9% w / v sodium chloride, (iv) a buffer concentration of 5 mM to 20 mM, and no or no more than 50 μM tryptophan and N-acetyl-tryptophan.
[0091] A preferred liquid formulation of the present invention comprises (i) botulinum toxin, (ii) HSA, (iii) sodium chloride as a tonicity agent, and (iv) a buffer selected from the group consisting of histidine, phosphates, and mixtures thereof as buffers, wherein the buffer is preferably histidine and contains no or no more than 50 μM tryptophan and N-acetyl-tryptophan.
[0092] A particularly preferred liquid formulation comprises (i) botulinum toxin in a concentration of 10 U / ml to 200 U / ml, (ii) HSA in an amount of 0.01% w / v to 1.0% w / v, (iii) sodium chloride in an amount of 0.01% w / v to 2.0% w / v, preferably 0.9% w / v, (iv) a buffer selected from histidine, phosphate and a mixture thereof in a concentration of 1 mM to 100 mM, wherein the buffer is preferably histidine in a concentration of 1 mM to 100 mM, and contains no or no more than 50 μM tryptophan and N-acetyl-tryptophan.
[0093] Another particularly preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10 U / ml to 200 U / ml, (ii) 0.01% w / v to 0.5% w / v HSA, (iii) 0.9% w / v sodium chloride, and (iv) a buffer selected from histidine, phosphate, and a mixture thereof at a concentration of 1 mM to 100 mM, wherein the buffer preferably has a concentration of histidine at a concentration of 1 mM to 100 mM, and contains no or no more than 50 μM tryptophan and N-acetyl-tryptophan.
[0094] Another particularly preferred liquid formulation of the present invention comprises (i) a botulinum toxin concentration of 10 U / ml to 200 U / ml, (ii) 0.05% w / v to 0.25% w / v HSA, (iii) 0.9% w / v sodium chloride, and (iv) a buffer selected from histidine, phosphate and a mixture thereof in a concentration of 1 mM to 100 mM, preferably in a concentration of 2 mM to 50 mM, more preferably in a concentration of 5 mM to 20 mM, wherein the buffer is preferably in a concentration of 1 mM to 100 mM, preferably in a concentration of 2 mM to 50 mM, more preferably in a concentration of 5 mM to 20 mM histidine, and contains no or no more than 50 μM tryptophan and N-acetyl-tryptophan.
[0095] Furthermore, the pH of the above preferred and particularly preferred liquid preparations is preferably in the range of 6.0 to 7.5, more preferably in the range of 6.5 to 7.0. Furthermore, the botulinum toxin is preferably serotype A, more preferably a neurotoxic component of serotype A.
[0096] Preferred exemplary liquid formulations of the present invention are as follows:
[0097] Preparation 1:
[0098] 50U / ml BoNT / A
[0099] 0.9% NaCI (9 mg / mL)
[0100] 0.085% HSA (purified, e.g. dialyzed) (0.85 mg / mL)
[0101] 0.155% Histidine (1.55 mg / ml; ~10 mM)
[0102] Trp and N-AcTrp < 50 μm
[0103] pH 6.0.
[0104] The purified HSA of exemplary formulation 1 can be prepared by the process described in detail in conjunction with the method according to the fourth aspect of the invention.
[0105] According to the present invention, the liquid formulation of the present invention is preferably prepared or obtained by a method according to the fourth aspect of the present invention. The method allows the removal of substances contained in the HSA starting material (e.g., commercial HSA products), including N-acetyl-tryptophan, which would destroy the photostability of the liquid botulinum toxin formulation.
[0106] In a third aspect, the present invention relates to a liquid formulation comprising:
[0107] (i) Botulinum toxin and
[0108] (ii) human serum albumin (HSA),
[0109] Wherein the liquid preparation is prepared by a method comprising the following steps:
[0110] (a) contacting human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and
[0111] (b) removing the chelating agent from the mixture.
[0112] Regarding component (i) of the liquid formulation of the present invention, the botulinum toxin is not particularly limited, and includes botulinum toxin of any serotype (eg, BoNT / AG). Preferably, the botulinum toxin is as defined above.
[0113] With respect to component (ii) of the liquid formulation, "human serum albumin" or "HSA" refers to donor HSA and recombinant HSA, preferably donor HSA, as defined above. HSA may be present in the liquid formulation in an amount of 0.001-2.0% w / v, preferably in an amount of 0.001-1.00% w / v, more preferably in an amount of 0.01-0.5% w / v, still more preferably in an amount of 0.02-0.3% w / v, and most preferably in an amount of 0.03-0.15% w / v.
[0114] According to the present invention, the liquid preparation of the present invention is prepared by a method comprising at least steps (a) and (b), wherein the first step is as follows:
[0115] (a) contacting human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent.
[0116] As used herein, the term "contacting" is intended to be broadly interpreted as bringing two or more components together. This can be achieved by various methods, such as dissolving, mixing, suspending, blending, slurrying, stirring, flowing through, adsorbing, combining, extracting, etc. Typically, the chelating agent is added to a composition comprising HSA (e.g., a HSA solution), followed by mixing to obtain a homogenous mixture, and optionally further processing steps (e.g., dialysis against a buffer containing the chelating agent).
[0117] Therefore, it is also contemplated that "contacting" can be achieved by loading the HSA material, for example in the form of an aqueous solution, onto an immobilized metal affinity resin (IMAC). The term "immobilized metal affinity resin" (IMAC) as used herein includes, but is not limited to, resins containing immobilized functional moieties (e.g., iminodiacetic acid) capable of binding and coordinating multivalent cations, such as chelate-agarose gel, Fractogel-EMD-chelate, POROS 20MC, Matrex Cellufine chelate, TALON and Chelex 100 resins. As known to those skilled in the art, such immobilized metal affinity resins are typically used in the form of chromatographic metal affinity columns. In addition, as used herein, the term "contacting" also includes batch mode binding using a suitable immobilized metal affinity resin.
[0118] Regarding step (a), it should also be noted that the terms "human serum albumin" and "chelating agent" used in step (a) of the method for preparing the liquid preparation of the present invention do not imply any limitation on their physical form, nor do they exclude the presence of other substances or compounds mixed with or contained in HSA and the chelating agent. This means that the "human serum albumin" contacted with the chelating agent in step (a) may be in any form, such as in the form of a solid or liquid (e.g., an aqueous composition or an aqueous solution). Similarly, the "chelating agent" contacted with the human serum albumin in step (a) may be in any form, such as in the form of a solid or liquid (e.g., an aqueous composition or an aqueous solution). Furthermore, the expression “contacting human serum albumin with a chelating agent” does not exclude that (i) human serum albumin is in the form of a composition (e.g., a solid composition or a liquid composition, in particular an aqueous composition or an aqueous solution) comprising one or more other components contained in the final liquid formulation, such as a tonicity agent or a buffer, and / or (ii) the chelating agent is in the form of a composition (e.g., a solid composition or a liquid composition, in particular an aqueous composition or an aqueous solution) comprising one or more other components contained in the final liquid formulation, such as a tonicity agent or a buffer.
[0119] Preferably, the mixture obtained in step (a) is an aqueous mixture. Such an aqueous mixture can be prepared in different ways. For example, human serum albumin can be in the form of an aqueous composition, such as an aqueous solution, which is mixed with a chelating agent that can be in solid form or liquid form (e.g. in the form of an aqueous solution of the chelating agent). In addition, human serum albumin can be in solid form, such as a lyophilized material, which is mixed with a chelating agent and an aqueous solution or an aqueous solution of the chelating agent. Preferably, human serum albumin is in the form of an aqueous composition, more preferably an aqueous solution, and the chelating agent is a solid or an aqueous composition (e.g. an aqueous solution).
[0120] In particular, the HSA contacted with the chelating agent in step (a) may be in the form of an aqueous solution comprising at least 5% w / v HSA, more preferably 10-30% w / v HSA, most preferably 20% w / v HSA. In addition, the pH of the mixture obtained in step (a) may be adjusted to within the range of 6.0-9.0, preferably 6.5-8.5, more preferably 7.0-8.5, most preferably 7.0-8.0.
[0121] In addition, the contacting step (a) of the method for preparing a liquid formulation according to the present invention may include several sub-steps. For example, in one embodiment, the contacting step (a) includes the following steps: mixing a chelating agent (e.g., EDTA) and human serum albumin, incubating the mixture for a determined time, and optionally dialyzing the mixture against a buffer containing a chelating agent, the chelating agent is preferably the same as that used in the incubation sub-step; or the contacting step (a) (only) consists of the steps. In another embodiment, the mixture is not incubated, but is dialyzed (directly) in a buffer containing a chelating agent, the chelating agent is preferably the same as that used in the step of mixing the chelating agent (e.g., EDTA) and human serum albumin. In another embodiment, the chelating agent and human serum albumin are not mixed before dialysis. That is, the contacting step (a) may include the step of dialyzing the mixture against a buffer containing a chelating agent; or (only) consists of the step of dialyzing the mixture against a buffer containing a chelating agent.
[0122] Preferably, step (a) comprises the step of adding a chelating agent to a composition comprising HSA (e.g., an HSA solution), or the step of mixing a chelating agent with a composition comprising HSA (e.g., an HSA solution), or (only) consists of the steps. The resulting mixture is then incubated for a period of time, for example, left to stand for a given time without stirring, or stirred for a given time.
[0123] Incubation time is not limited to a specific range, but is generally at least 0.5 hours, particularly at least 1 hour, more particularly at least 2 hours. The upper limit of the incubation time is not important, and can be, for example, 1 hour, 2 hours, 5 hours or 10 hours. Therefore, the incubation time can be, for example, 0.5 to 5 hours or 1 hour to 10 hours. Similarly, the incubation temperature is not particularly limited, for example, can be in the range of 0 ° C to 60 ° C. Preferably, the temperature is 0 ° C to 30 ° C. This means that room temperature (20 ° C or 25 ° C) is a suitable temperature in the present invention. As known to the technician, temperature affects the reaction time. Typically, incubation conditions (such as time and temperature) are selected so that the residual amount of the chelating agent (such as EDTA) contained in the final product is 100 μM or less, preferably 10 μM or less, more preferably 1 μM or less.
[0124] Optionally, the incubation step is followed by further treatment, such as dialyzing the incubated mixture with a buffer containing a chelating agent, which is generally the same as the chelating agent used in the incubation step. The chelating agent used in this optional dialysis step is preferably contained in the dialysis buffer at a concentration of 0.1 mM-1000 mM, more preferably 1 mM-200 mM, most preferably 10 mM-100 mM. It is also preferred that the buffer (i) used in the dialysis step has a pH of 7.5-8.5, (ii) preferably also comprises a buffer according to the final composition, or (iii) also comprises a tonicity agent, preferably 0.9% sodium chloride w / v, or (i) and (ii), or (i) and (iii), or (ii) and (iii), or (i) and (ii) and (iii).
[0125] In the present invention, the term "chelating agent" as used herein is not particularly limited as long as it can bind metal ions. The term "chelating agent" as used herein may also be referred to as a "chelating agent" or a "masking agent". The chelating agent used herein is generally an organic compound that binds metal ions. Metal ions generally form multiple coordination bonds with organic chelating agents that are multidentate ligands.
[0126] Suitable chelating agents for use herein include, but are not limited to, aminopolycarboxylic acids (e.g., aminopolycarboxylic acids having three to six, preferably four, carboxylic acid functional groups) and other compounds such as citrates, porphyrins, TPEN (N,N,N',N'-tetrakis(2-pyridylmethyl)-1,2-ethylenediamine), TETA (triethylenetetramine), and mixtures thereof. Exemplary aminopolycarboxylic acids include NTA (nitrilotriacetate), DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate), TED (ethylenediaminetriacetate), EDTA (ethylenediaminetetraacetic acid), EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid), BAPTA (1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), DTPA (diethylenetriaminepentaacetic acid) and TTHA (triethylenetetraaminehexaacetic acid).
[0127] Particularly preferred chelating agents for use herein include compounds of general formula (I):
[0128] (HO2CCH2)2N-RN(CH2CO2H)2(I),
[0129] It is an aminopolycarboxylic acid compound with at least four carboxylic acid functional groups. The R group is not particularly limited and may not contain a carboxylic acid functional group or may contain one or two carboxylic acid functional groups. Preferably, the R group does not contain or contains a carboxylic acid functional group, most preferably does not contain a carboxylic acid functional group.
[0130] Examples of compounds of general formula (I) include, for example, EDTA, EGTA, BAPTA, DTPA and TTHA. EDTA, EGTA and DTPA are particularly preferred herein, EDTA and DTPA are more preferred, and EDTA is most preferred. A mixture of any of the above chelating agents may also be used in the present invention, for example as a solution, solid or coupled to a substrate.
[0131] In step (a), HSA is preferably contacted with an amount of chelating agent such that the chelating agent is present in the liquid preparation at a concentration of 0.1 mM-1000 mM or 0.1 mM-500 mM, more preferably 0.5 mM-500 mM or 1 mM-500 mM, most preferably 10 mM-100 mM.
[0132] According to the present invention, the method for preparing the liquid preparation also comprises the following steps:
[0133] (b) removing the chelating agent from the mixture.
[0134] In step (b), the chelating agent may be removed by any suitable technique, such as dialysis (including conventional dialysis using dialysis bags, countercurrent dialysis, etc.), reverse osmosis, filtration, cross-flow filtration, ultrafiltration, and chromatography (e.g., ion exchange chromatography or gel filtration chromatography).
[0135] Preferably, the chelating agent is removed by dialysis. The dialysis is usually carried out at a temperature of 0°C to 30°C, particularly at a temperature of 2°C to 30°C or 4°C to 25°C, including room temperature for 0.5-48 hours, particularly 1-24 hours or 1-12 hours. In addition, the dialysis is usually carried out in a dialysis buffer having a volume of 10 to 1000 times the volume of the incubated HSA / chelating agent mixture, and the dialysis buffer is usually replaced at least once. The dialysis membrane used can have a molecular weight cut-off of, for example, 10 kDa.
[0136] Typically, dialysis conditions (e.g., time, temperature, buffer volume, number of buffer changes) are selected so that the residual concentration of the chelating agent (e.g., EDTA) in the final product is 100 μM or less, preferably 10 μM or less, more preferably 1 μM or less.
[0137] According to a preferred embodiment of the present invention, the HSA starting material is first pretreated by contact with a chelating agent, and then the chelating agent is removed. The pretreated HSA thus obtained is then used to prepare the liquid botulinum toxin preparation of the present invention. As used herein, the term "human serum albumin starting material" refers to donor HSA material (derived from human blood, or more precisely, HSA derived from human plasma) or recombinant HSA material, which can be obtained through commercial or conventional routes, i.e., without the pretreatment described herein. The term "human serum albumin starting material" used herein also includes a mixture of donor HSA material and recombinant HSA material.
[0138] More specifically, according to this preferred embodiment, a liquid formulation comprising (i) botulinum toxin and (ii) human serum albumin is prepared by a method comprising the following steps:
[0139] (a) contacting a human serum albumin starting material with a chelating agent to obtain a mixture of the human serum albumin starting material and the chelating agent,
[0140] (b) removing the chelating agent from the mixture to obtain a pretreated human serum albumin material, and
[0141] (c) mixing botulinum toxin with the pre-treated human serum albumin material.
[0142] According to another preferred embodiment of the present invention, the liquid preformulation is contacted with a chelating agent and then the chelating agent is removed to obtain a liquid preparation. The term "liquid preformulation" as used herein refers to a liquid preparation containing at least components (i) and (ii) (i.e., botulinum toxin and HSA), preferably containing all components and substances contained in the final liquid composition, especially components (iii) and (iv). In the latter case, the treatment and removal of the chelating agent produces the final liquid preparation.
[0143] More specifically, according to this preferred embodiment, a liquid formulation comprising (i) botulinum toxin and (ii) human serum albumin is prepared by a method comprising the following steps:
[0144] (a) contacting a liquid preformulation comprising botulinum toxin and human serum albumin with a chelating agent to obtain a mixture of the liquid preformulation and the chelating agent, and
[0145] (b) removing the chelating agent from the mixture to obtain a liquid formulation.
[0146] According to the present invention, the liquid formulation (according to any aspect described herein, i.e. according to the first, second and third aspects) may optionally further comprise:
[0147] (iii) Tonicity agents.
[0148] As used herein, the term "tonicity agent" refers to an agent added to an injectable formulation to make the formulation similar to a physiological fluid in osmotic properties. A tonicity agent may also be referred to as an "osmotic regulator". There is no particular limitation to the tonicity agent, and for example, it may be selected from the group consisting of sugars, salts, polymers, and mixtures thereof.
[0149] Exemplary tonicity agents include sucrose, glucose, sodium carbonate, amino acids, polyethylene glycol (PEG), dextran, cyclodextrin and colloids (e.g., colloidal polysaccharides). Typically, the concentration of the tonicity agent is in the range of 0-2.0% w / v, particularly 0.01-2.0% w / v or 0.1-1.5% w / v, more particularly 0.6-1.2% w / v.
[0150] Preferably, the tonicity agent is sodium chloride (NaCl).Sodium chloride may be present in the liquid formulation of the present invention in an amount of 0.01-2.0% w / v, preferably 0.1-1.5% w / v, more preferably 0.5-1.2% w / v or 0.8-1.0% w / v, most preferably 0.9% w / v.
[0151] According to the present invention, the liquid formulation (according to any aspect described herein, i.e. according to the first, second and third aspects) may optionally further comprise:
[0152] (vi) Buffering agents.
[0153] The term "buffer" as used herein refers to an agent that maintains the pH of a liquid formulation within an acceptable range, i.e., an agent that can control the pH of the formulation. Suitable buffers are those that do not chemically react with the other ingredients, and are present in an amount sufficient to provide the desired degree of pH buffering. Such buffers include, for example, amino acids, acetates, malic acid, ascorbate, citrate, tartrate, fumarate, succinate, phosphate, bicarbonate, TRIS, Bis-TRIS, ACES, MES, BES, MOPS, HEPES, TES, PIPES, tris(hydroxymethyl)methylglycine, and imidazoles.
[0154] Preferably, the buffer is phosphate (i.e. phosphate buffer), amino acid or a mixture thereof. The term "phosphate" as used herein generally refers to unprotonated and protonated forms and any salts thereof. The amino acid can be selected from aspartic acid, glycine, glutamic acid, histidine, proline, taurine, methionine, serine, tyrosine, tryptophan and mixtures thereof, preferably from histidine, proline, taurine, methionine, serine, tyrosine and mixtures thereof. Most preferably, the amino acid is histidine. The most preferred buffer used herein is histidine, phosphate or a mixture thereof.
[0155] The concentration of the buffer in the liquid preparation of the present invention is preferably 1-100mM, preferably 2-50mM, more preferably 5-20mM. If the buffer is an amino acid (e.g., histidine), it can be present in the liquid preparation at a concentration of 1-100mM, preferably 2-50mM, more preferably 5-20mM, and most preferably 10mM. If the buffer is a phosphate, it can be present in the liquid preparation at a concentration of 1-100mM, preferably 2-50mM, more preferably 5-20mM, and most preferably 10mM.
[0156] In addition, liquid preparation of the present invention can further comprise one or more other pharmaceutically acceptable excipients, unless otherwise specified or intended.For example, liquid preparation can comprise one or more in glycerol, sucrose, lactose, mannitol, dextran, hyaluronic acid, polyvinylpyrrolidone, lactic acid, citric acid, amino acid, benzyl alcohol, lidocaine, gelatin, hydroxyethyl starch (HES), polyethylene oxide and polysorbate (for example, polysorbate 20, polysorbate 80).Other suitable pharmaceutically acceptable excipients include those well known in the art, referring to for example Remington's PharmaceuticalSciences, Mack Publishing Company, Easton, Pennsylvania.
[0157] On the other hand, it is also contemplated herein that the liquid formulations of the present invention are particularly lacking certain components (i.e., compounds, materials, or substances), such as chelating agents, detergents, polysaccharides, amino acids, stabilizing peptides, and the like, including any combination thereof. As used herein, the term "detergent" is synonymous with "surfactant" and is intended to include nonionic and ionic detergents. The term "stabilizing peptide" used herein generally refers to a peptide consisting of 5 to 50 amino acids, such as 10 to 40 amino acids or 15 to 30 amino acids. Therefore, the term "stabilizing peptide" does not include HSA.
[0158] In one embodiment, the liquid preparation of the present invention does not contain detergent, particularly does not contain polysorbate, more particularly does not contain polysorbate 20 and / or polysorbate 80. In another embodiment, the liquid preparation of the present invention does not contain alginate. In another embodiment, the liquid preparation of the present invention does not contain succinate. In another embodiment, the liquid preparation of the present invention does not contain one or more (e.g., 2, 3, 4 or 5 kinds) of amino acids selected from the group consisting of arginine, glutamic acid, methionine, tryptophan and serine. In another embodiment, the liquid preparation of the present invention does not contain carbohydrates, such as monosaccharides, oligosaccharides or polysaccharides or mixtures thereof. In particular, the liquid preparation of the present invention may not include one or more (e.g., 2, 3 or 4 kinds) of sucrose, lactose, maltose and trehalose. In another embodiment, the liquid preparation of the present invention does not contain chelating agents, particularly those described herein in conjunction with the present invention. It is also contemplated in the present invention that the liquid preparation lacks more than one or all of the above compounds.
[0159] In one embodiment, the liquid formulation of the present invention lacks (i) detergents and monosaccharides, oligosaccharides and polysaccharides, (ii) detergents and any amino acids, or detergents and all amino acids except histidine, (iii) detergents and stabilizing peptides, (iv) monosaccharides, oligosaccharides and polysaccharides and any amino acids, or monosaccharides, oligosaccharides and polysaccharides and all amino acids except histidine, (v) monosaccharides, oligosaccharides and polysaccharides and stabilizing peptides, (vi) any amino acids and stabilizing peptides, or all amino acids except histidine and stabilizing peptides, (vii) detergents, monosaccharides, oligosaccharides and polysaccharides and any amino acids, or detergents, monosaccharides, Oligosaccharides and polysaccharides and all amino acids except histidine, (viii) detergents, monosaccharides, oligosaccharides and polysaccharides, and stable peptides, (ix) detergents, any amino acids, and stable peptides, or detergents, all amino acids except histidine, and stable peptides, (x) monosaccharides, oligosaccharides and polysaccharides, any amino acids, and stable peptides, or monosaccharides, oligosaccharides and polysaccharides, all amino acids except histidine, and stable peptides, (xi) detergents, monosaccharides, oligosaccharides and polysaccharides, any amino acids and stable peptides, or detergents, monosaccharides, oligosaccharides and polysaccharides, all amino acids except histidine, and stable peptides.
[0160] In another embodiment, the liquid formulation of the present invention does not contain any other amino acids except histidine. In another embodiment, the liquid formulation of the present invention does not contain any monosaccharides, disaccharides and trisaccharides. In another embodiment, the liquid formulation of the present invention does not contain any other stabilizing peptides or proteins except HSA. In another embodiment, the liquid formulation of the present invention does not contain phosphates, such as phosphates in the form of phosphate buffers.
[0161] In other embodiments, the liquid formulations of the invention lack (i) succinate and a detergent (e.g., polysorbate), (ii) succinate and methionine, (iii) succinate and sucrose, (iv) a detergent (e.g., polysorbate) and methionine, (v) a detergent (e.g., polysorbate) and sucrose, (vi) methionine and sucrose, (vii) succinate, a detergent (e.g., polysorbate) and methionine, (vii) succinate, a detergent (e.g., polysorbate) and methionine, ( xiii) succinate, a detergent (e.g., polysorbate) and sucrose, (ix) succinate, methionine and sucrose, (x) a detergent (e.g., polysorbate), methionine and sucrose, and (xi) succinate, a detergent (e.g., polysorbate), methionine and sucrose, (xii) a detergent (e.g., polysorbate and histidine, (xiii) a detergent (e.g., polysorbate), histidine and sucrose).
[0162] Furthermore, any liquid formulation of the invention lacking one or more components (ie, compounds, materials or substances) may also lack a chelating agent, particularly a chelating agent as described herein.
[0163] In addition, a preferred liquid formulation of the present invention comprises (i) botulinum toxin, (ii) HSA, and (iii) a tonicity agent. A preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.01-1.0% w / v HSA, and (iii) 0.01-2.0% w / v of a tonicity agent, preferably sodium chloride. A preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.01-0.5% w / v HSA, and (iii) 0.1-1.5% w / v of a tonicity agent, preferably sodium chloride. A preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.05-0.25% w / v HSA, and (iii) 0.6-1.2% w / v of a tonicity agent, preferably sodium chloride. A preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.01-0.5% w / v HSA, and (iii) 0.9% w / v sodium chloride as a tonicity agent. A preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.05-0.25% w / v HSA, and (iii) 0.9% w / v sodium chloride as a tonicity agent.
[0164] Also contemplated herein are preferred liquid formulations described in the preceding and following paragraphs characterized by Fe 3+ The concentration of the ions is less than 1 μM, preferably less than 1000 nM or less than 500 nM, more preferably less than 250 nM or less than 100 nM, most preferably less than 10 nM or less than 1 nM.
[0165] Preferred liquid formulations of the present invention comprise (i) botulinum toxin, (ii) HSA, (iii) a tonicity agent, and (iv) a buffer. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.01-1.0% w / v HSA, (iii) 0.01-2.0% w / v of a tonicity agent, preferably sodium chloride, and (iv) a buffer at a concentration of 1-100 mM. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.01-0.5% w / v HSA, (iii) 0.01-2.0% w / v of a tonicity agent, preferably sodium chloride, and (iv) a buffer at a concentration of 1-100 mM. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.05-0.25% w / v HSA, (iii) 0.1-2.0% w / v tonicity agent, preferably sodium chloride, and (iv) a buffer at a concentration of 1-100 mM. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.05-0.25% w / v HSA, (iii) 0.6-1.3% w / v tonicity agent, preferably sodium chloride, and (iv) a buffer at a concentration of 2-50 mM. Preferred liquid formulations of the present invention comprise (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.05-0.25% w / v HSA, (iii) 0.9% w / v sodium chloride, and (iv) a buffer at a concentration of 5-20 mM. It is also contemplated herein that the preferred liquid formulations described in this paragraph are characterized by Fe 3+ The concentration of the ions is less than 1 μM, preferably less than 1000 nM or less than 500 nM, more preferably less than 250 nM or less than 100 nM, most preferably less than 10 nM or less than 1 nM.
[0166] A preferred liquid formulation of the present invention comprises (i) botulinum toxin, (ii) HSA, (iii) sodium chloride as a tonicity agent, and (iv) a buffer selected from the group consisting of histidine, phosphates and mixtures thereof as buffers, wherein the buffer is preferably histidine.
[0167] A particularly preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.01-1.0% w / v HSA, (iii) 0.01-2.0% w / v, preferably 0.9% w / v sodium chloride, and (iv) a buffer selected from histidine, phosphate and a mixture thereof at a concentration of 1-100 mM, wherein the buffer is preferably histidine at a concentration of 1-100 mM.
[0168] Another particularly preferred liquid formulation of the present invention comprises (i) a botulinum toxin at a concentration of 10-200 U / ml, (ii) 0.01-0.5% w / v HSA, (iii) 0.9% w / v sodium chloride, and (iv) a buffer selected from histidine, phosphate and a mixture thereof at a concentration of 1-100 mM, wherein the buffer is preferably histidine at a concentration of 1-100 mM.
[0169] Another particularly preferred liquid formulation of the present invention comprises (i) a botulinum toxin concentration of 10-200 U / ml, (ii) 0.05-0.25% w / v HSA, (iii) 0.9% w / v sodium chloride, and (iv) a buffer selected from histidine, phosphate and a mixture thereof at a concentration of 1-100 mM, preferably 2 mM-50 mM, or more preferably 5 mM-20 mM, wherein the buffer is preferably at a concentration of 1-100 mM, preferably 2 mM to 50 mM, more preferably 5 mM to 20 mM histidine.
[0170] Furthermore, the pH of the above preferred and particularly preferred liquid preparations is preferably in the range of 6.0 to 7.5. Furthermore, the botulinum toxin is preferably serotype A, more preferably a neurotoxic component of serotype A.
[0171] Preferred exemplary liquid formulations of the present invention are as follows:
[0172] Preparation 1:
[0173] 50U / ml BoNT / A
[0174] 0.9% NaCI (9 mg / mL)
[0175] 0.085% HSA (EDTA dialyzed) (0.85mg / mL)
[0176] 0.155% Histidine (1.55 mg / ml; ~10 mM)
[0177] pH 6.0
[0178] HSA (EDTA dialyzed) of Exemplary Formulation 1 was prepared by an exemplary method comprising the following steps:
[0179] - Add 37.2 mg Na2-EDTA per ml of 20% HSA solution under stirring and adjust the pH to 8.0 with NaOH,
[0180] - Incubate with agitation at room temperature for 6 hours,
[0181] - Dialyze against 100 volumes of EDTA buffer (100 mM Na2-EDTA; 10 mM histidine; 0.9% NaCl pH 7.0) at room temperature for 16 hours with gentle stirring on a magnetic stirrer (MWCO of the dialysis membrane is 10 kDa)
[0182] - Dialyze against 100 volumes of 10 mM histidine, 0.9% NaCl pH 6.0 at room temperature for 24 hours, then replace the dialysis buffer with fresh buffer and dialyze for another 24 hours, and repeat two more times.
[0183] In exemplary formulation 1, EDTA can optionally be replaced by other chelating agents, such as EGTA, BAPTA or DTPA. As an alternative to adding solid EDTA to the HSA solution, a concentrated EDTA solution (e.g., 200 mM EDTA, pH 8.0) can be used. The first dialysis step (to EDTA buffer) can also be omitted. Other methods, such as cross-flow dialysis or ultrafiltration, can also be used instead of dialysis.
[0184] The present invention also relates to a liquid preparation containing botulinum toxin, wherein after the liquid preparation is stored at a high temperature of 40°C for 4 weeks, the toxin activity is reduced by no more than 20% relative to the initial toxin activity. In addition, the present invention relates to a liquid preparation containing botulinum toxin, wherein the liquid preparation is exposed to 250W / m 2 After 7 hours at 250 W / m2, the toxin activity does not decrease by more than 20% relative to the initial toxin activity. Preferably, for the light stability test, i.e., for the light stability test at 250 W / m2, the toxin activity does not decrease by more than 20% relative to the initial toxin activity. 2 For exposure to sunlight for 7 hours, a SUNTEST CPS+ instrument (ATLAS Material Testing Technology LLC) can be used, which is equipped with a filter set to provide a spectral distribution in the wavelength range of 320-800 nm, which corresponds to ID65 (indoor indirect daylight standard) of ISO 10977, using a window glass filter according to ICH Q1B.
[0185] In addition, the present invention also relates to a method for preparing the liquid botulinum toxin preparation described herein, comprising adding the components described herein, in particular components (i) to (ii), and optionally one or more components (iii) and (vi), preferably components (i), (ii), (iii) and (iv). The preparation of the liquid preparation of the present invention is not particularly limited, and the corresponding preparation technology is known to those skilled in the art. As mentioned above, the liquid preparation of botulinum toxin is usually an aqueous solution, preferably a saline solution, more preferably a physiological saline solution, and most preferably a buffered (e.g., phosphate or histidine buffered) physiological saline solution.
[0186] Preferably, the salt is dissolved first, then the HSA is added, the pH is adjusted if necessary, and finally the botulinum toxin is added. This order is not mandatory but is considered to safely maintain the maximum specific activity of the BoNT. Preferably, the method of preparing a liquid botulinum toxin formulation does not include reconstitution of a lyophilized botulinum toxin formulation in powder form.
[0187] Furthermore, the present invention relates to a method of stabilizing a liquid botulinum toxin formulation, the method comprising combining a botulinum toxin with human serum albumin (HSA), wherein the HSA is prepared by a method comprising the steps of:
[0188] (a) contacting a composition comprising human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and
[0189] (b) removing the chelating agent from the mixture.
[0190] Additionally, the present invention relates to the use of human serum albumin (HSA) for increasing the light and / or temperature stability of a liquid composition comprising botulinum toxin, wherein the HSA is prepared by a process comprising the following steps:
[0191] (a) contacting a composition comprising human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and
[0192] (b) removing the chelating agent from the mixture.
[0193] Furthermore, the present invention relates to human serum albumin (HSA), which can be obtained by the following method
[0194] (a) contacting a composition comprising human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and
[0195] (b) removing the chelating agent from the mixture.
[0196] In a fourth aspect, the present invention relates to a method for preparing a liquid formulation, wherein the method comprises the following steps:
[0197] - purifying the human serum albumin starting material to obtain a purified human serum albumin material,
[0198] - mixing the obtained purified human serum albumin with botulinum toxin and optionally other components to obtain a liquid preparation,
[0199] or
[0200] - purifying a liquid composition comprising botulinum toxin and human serum albumin to obtain a purified liquid composition,
[0201] - The purified liquid composition obtained is mixed with other components to obtain a liquid preparation.
[0202] The human serum albumin starting material is as defined above. Preferably, it is in the form of an aqueous solution, containing at least 5% weight / volume of HSA, preferably 10% weight / volume to 35% weight / volume of HSA, more preferably 15% weight / volume to 30% weight / volume, most preferably 20% weight / volume to 25% weight / volume of HSA. The human serum albumin starting starting material may contain tryptophan and N-acetyl-tryptophan, in particular N-acetyl-tryptophan, in an amount greater than 5mM, 10mM or more, 20mM or more, or 30mM or more. In addition, the pH of the mixture obtained in step (a) can be adjusted to 6.0 to 9.0, preferably 6.5 to 8.5, more preferably 7.0 to 8.5, and most preferably in the range of 7.0 to 8.0.
[0203] Preferably, in a first alternative of the method of the invention, the purification step results in a purified human serum albumin material that contains no or no more than 5 mM, preferably no more than 1 mM, more preferably no more than 0.1 mM, most preferably no more than 0.001 mM tryptophan and / or N-acetyl-tryptophan. When preparing a liquid formulation, the purified human serum albumin material is diluted so that the concentration of tryptophan and N-acetyl-tryptophan falls within the range described herein, for example, less than 50 μM.
[0204] The purification step can be performed by subjecting the human serum albumin starting material or the liquid composition comprising botulinum toxin and human serum albumin to dialysis, diafiltration (cross-flow filtration), ultrafiltration, chromatographic purification techniques such as ion exchange chromatography (IEX), affinity chromatography and hydrophobic interaction chromatography (HIC), field flow fractionation or precipitation (e.g., salt precipitation, ethanol precipitation).
[0205] Preferably, purification is performed by dialysis. Dialysis is usually performed at a temperature of 0°C to 30°C, particularly at a temperature of 2°C to 30°C or 4°C to 25°C, including room temperature for 0.5-48 hours, particularly 1-24 hours or 1-12 hours. In addition, dialysis is usually performed in a dialysis buffer having a volume of 10 to 1000 times the volume of the incubated HSA solution, and the dialysis buffer is usually replaced at least once. The dialysis membrane used can have, for example, a molecular weight cutoff of 10 kDa.
[0206] For example, purified serum albumin can be obtained by the following method:
[0207] - Dialyze the commercially available HSA product with 100 volumes of dialysis buffer (10 mM histidine, 0.9% NaCl, pH 6.0) for 24 hours at room temperature under gentle stirring with a magnetic stirrer (MWCO of the dialysis membrane is 10 kDa),
[0208] - Replace the buffer with fresh dialysis buffer and dialyze for 24 hours at room temperature and repeat two more times.
[0209] The first alternative to the above method, i.e. purifying the human serum albumin starting material and mixing the purified human serum albumin obtained with the botulinum toxin and optionally other components, is preferred in the present invention. The mixing step for obtaining the liquid preparation of the present invention is not particularly limited and comprises mixing components (i) to (ii) and optionally one or more components (iii) and (vi). Preferably, the salt is dissolved first, then HSA is added, the pH is adjusted if necessary, and finally the botulinum toxin is added. This order is not a mandatory requirement, but is considered to safely maintain the maximum specific activity of BoNT. Preferably, the method for preparing a liquid botulinum toxin preparation does not include the reconstitution of a freeze-dried botulinum toxin preparation in powder form.
[0210] As described above with respect to the first aspect of the invention, it is also contemplated herein that the liquid formulations of the invention have low Fe 3+ Ion concentration, because Fe 3+ Ions also have a destabilizing effect on photostability. Therefore, according to the present invention, in order to remove Fe 3+ Ions, the purification step according to the method of the present invention is carried out as follows or additionally comprises the following steps:
[0211] - contacting a human serum albumin starting material with a chelating agent to obtain a mixture of the human serum albumin starting material and the chelating agent, and
[0212] - removing the chelating agent from the mixture to obtain a chelating agent-treated purified human serum albumin material, or
[0213] - contacting a liquid composition comprising botulinum toxin and human serum albumin with a chelating agent to obtain a mixture of the liquid composition and the chelating agent, and
[0214] - Removing the chelating agent from the mixture to obtain a chelating agent treated purified liquid preparation.
[0215] In the contacting step, the human serum albumin starting material and the liquid composition comprising botulinum toxin and human serum albumin are each preferably contacted with an amount of chelating agent such that the chelating agent is present in the mixture at a concentration of 0.1 mM to 1000 mM or 0.1 mM to 500 mM, more preferably 0.5 mM to 500 mM or 1 mM to 500 mM, most preferably 10 mM to 100 mM.
[0216] Removal of the chelating agent can be performed by dialysis, cross-flow filtration or ultrafiltration.
[0217] As used herein, the term "contacting" is intended to be broadly interpreted as bringing two or more components together. This can be achieved by various methods, such as dissolving, mixing, suspending, blending, slurrying, stirring, flowing through, adsorbing, combining, extracting, etc. Typically, the chelating agent is added to a composition comprising HSA (e.g., a HSA solution), followed by mixing to obtain a homogenous mixture, and optionally further processing steps (e.g., dialysis against a buffer containing the chelating agent).
[0218] Therefore, it is also contemplated herein that "contacting" can be carried out by loading the HSA material, for example in the form of an aqueous solution, onto an immobilized metal affinity resin (IMAC). The term "immobilized metal affinity resin" (IMAC) used herein includes, but is not limited to, resins containing immobilized functional parts (e.g., iminodiacetic acid) capable of binding and coordinating multivalent cations, such as chelate-agarose gel, Fractogel-EMD-chelate, POROS20MC, Matrex Cellufine chelate, TALON and Chelex 100 resins. As known to those skilled in the art, such immobilized metal affinity resins are typically used in the form of chromatographic metal affinity columns. In addition, as used herein, the term "contacting" also includes batch mode binding using a suitable immobilized metal affinity resin.
[0219] With regard to the contacting step, it should also be noted that the terms "human serum albumin starting material" and "chelating agent" used in the definition of the contacting step do not imply any limitation on their physical form, nor do they exclude the presence of other substances or compounds mixed with or contained in HSA and the chelating agent. This means that the "human serum albumin starting material" contacted with the chelating agent can be in any form, such as in the form of a solid or liquid (e.g., an aqueous composition or an aqueous solution). Similarly, the "chelating agent" contacted with the human serum albumin starting material can be in any form, such as in the form of a solid or liquid (e.g., an aqueous composition or an aqueous solution).
[0220] Preferably, the mixture obtained in the contacting step is an aqueous mixture. Such an aqueous mixture can be prepared in different ways. For example, human serum albumin can be in the form of an aqueous composition, such as an aqueous solution, mixed with a chelating agent that can be in solid form or in liquid form (e.g. in the form of an aqueous solution of the chelating agent). In addition, human serum albumin can be in solid form, such as a lyophilized material, mixed with a chelating agent and an aqueous solution or an aqueous solution of the chelating agent. Preferably, human serum albumin is in the form of an aqueous composition, more preferably an aqueous solution, and the chelating agent is a solid or an aqueous composition (e.g. an aqueous solution).
[0221] In particular, the HSA contacted with the chelating agent in the contacting step may be in the form of an aqueous solution comprising at least 5% w / v HSA, preferably 10% w / v to 35% w / v HSA, more preferably 15% w / v to 30% w / v HSA, most preferably 20% w / v to 25% w / v HSA. In addition, the pH of the mixture obtained in step (a) may be adjusted to within the range of 6.0 to 9.0, preferably 6.5 to 8.5, more preferably 7.0 to 8.5, most preferably 7.0 to 8.0.
[0222] In addition, the contacting step of the method for preparing a liquid formulation according to the present invention may include several sub-steps. For example, in one embodiment, the contacting step includes the following steps: mixing a chelating agent (e.g., EDTA) and human serum albumin, incubating the mixture for a determined time, and optionally dialyzing the mixture against a buffer containing a chelating agent, the chelating agent is preferably the same as that used in the incubation sub-step; or the contacting step (only) consists of the steps. In another embodiment, the mixture is not incubated, but is (directly) dialyzed in a buffer containing a chelating agent, the chelating agent is preferably the same as that used in the step of mixing the chelating agent (e.g., EDTA) and human serum albumin. In another embodiment, the chelating agent and human serum albumin are not mixed before dialysis. That is, the contacting step (a) may include the step of dialyzing the mixture against a buffer containing a chelating agent; or (only) consists of the step of dialyzing the mixture against a buffer containing a chelating agent.
[0223] Preferably, the contacting step comprises or consists of a step of adding a chelating agent to a composition comprising HSA (e.g., a HSA solution), or a step of mixing a chelating agent with a composition comprising HSA (e.g., a HSA solution), and then incubating the resulting mixture for a period of time, for example, standing for a given time without stirring, or stirring for a given time.
[0224] Incubation time is not limited to a specific range, but is generally at least 0.5 hours, particularly at least 1 hour, more particularly at least 2 hours. The upper limit of the incubation time is not important, and can be, for example, 1 hour, 2 hours, 5 hours or 10 hours. Therefore, the incubation time can be, for example, 0.5 to 5 hours or 1 hour to 10 hours. Similarly, the incubation temperature is not particularly limited, for example, can be in the range of 0 ° C to 60 ° C. Preferably, the temperature is 0 ° C to 30 ° C. This means that room temperature (20 ° C or 25 ° C) is a suitable temperature in the present invention. As known to the technician, temperature affects the reaction time. Typically, incubation conditions (such as time and temperature) are selected so that the residual amount of the chelating agent (such as EDTA) contained in the final product is 100 μM or less, preferably 10 μM or less, more preferably 1 μM or less.
[0225] Optionally, the incubation step is followed by further treatment, such as dialyzing the incubated mixture with a buffer containing a chelating agent, which is generally the same as the chelating agent used in the incubation step. The chelating agent used in this optional dialysis step is preferably contained in the dialysis buffer at a concentration of 0.1 mM-1000 mM, more preferably 1 mM-200 mM, most preferably 10 mM-100 mM. It is also preferred that the buffer (i) used in the dialysis step has a pH of 7.5-8.5, (ii) preferably also comprises a buffer according to the final composition, or (iii) also comprises a tonicity agent, preferably 0.9% sodium chloride w / v, or (i) and (ii), or (i) and (iii), or (ii) and (iii), or (i) and (ii) and (iii).
[0226] Chelating agents suitable for use herein are as defined above. Mixtures of any of the above chelating agents may also be used in the present invention, for example as a solution, solid or coupled to a matrix.
[0227] According to the present invention, the chelating agent can be removed by any suitable technique, such as dialysis (including conventional dialysis using dialysis bags, countercurrent dialysis, etc.), reverse osmosis, filtration, cross-flow filtration, ultrafiltration and chromatography (e.g., ion exchange chromatography or gel filtration chromatography).
[0228] Preferably, the chelating agent is removed by dialysis. The dialysis is usually carried out at a temperature of 0°C to 30°C, in particular at a temperature of 2°C to 30°C or 4°C to 25°C, including room temperature for 0.5-48 hours, in particular 1-24 hours or 1-12 hours. In addition, the dialysis is usually carried out in a dialysis buffer having a volume of 10 to 1000 times the volume of the incubated HSA / chelating agent mixture, and the dialysis buffer is usually replaced at least once. The dialysis membrane used can have a molecular weight cutoff of, for example, 10 kDa.
[0229] Typically, dialysis conditions (e.g., time, temperature, buffer volume, number of buffer changes) are selected so that the residual concentration of the chelating agent (e.g., EDTA) in the final product is 100 μM or less, preferably 10 μM or less, more preferably 1 μM or less.
[0230] In a fifth aspect, the present invention relates to a liquid formulation of the present invention for use in therapy.
[0231] In particular, the liquid preparation of the present invention can be used to treat neuromuscular diseases, pain, salivation, hyperhidrosis, urinary system diseases and nervous system diseases.
[0232] Exemplary neuromuscular diseases include dystonia, cervical dystonia, spasticity, post-stroke spasticity, blepharospasm, tremor, hyperkinetic movement disorders, and cerebral palsy. Urinary disorders include diseases characterized by detrusor overactivity, overactive bladder, neurogenic bladder, and interstitial cystitis, treatment of vulvodynia and chronic pelvic pain, benign prostatic hyperplasia (BPH), and detrusor sphincter dyssynergia (DSD). Exemplary neurological disorders include chronic migraine, trigeminal neuralgia, peripheral neuropathy pain, diabetic neuropathy pain, and depression.
[0233] In a sixth aspect, the present invention relates to the cosmetic use of the liquid formulation of the present invention for treating a cosmetic condition.
[0234] This aspect of the invention relates to the purely aesthetic use of the liquid formulation of the invention.Preferred cosmetic conditions to be treated include skin conditions, in particular the treatment of skin wrinkles, especially the treatment of facial wrinkles.
[0235] The term "wrinkle" as used herein should be interpreted broadly to include not only wrinkles, but also lines, textures, creases, grooves and folds. The words "lines", "wrinkles", "texture", "creases" and "folds" have similar definitions and are therefore often used interchangeably. In the present invention, "lines" are generally interchangeable with "wrinkles", but preferably refer to skin depressions that are less deep than "wrinkles". "Folds" are interchangeable with wrinkles and lines, preferably linear depressions. "Crease" is interchangeable with wrinkles, lines and folds. It preferably refers to a mild form of wrinkle, and can describe a specific wrinkle in a specific location. "Texture" as used herein has essentially the same meaning as wrinkles. However, "texture" preferably refers to a skin structure formed by irregularly gathered lines. "Flanges" are deep folds or deep lines on the skin.
[0236] Preferably, the wrinkles treated according to the present invention are facial wrinkles, including horizontal forehead lines, glabellar frown lines, periorbital wrinkles, crow's feet, harelip lines (i.e., lines radiating downward on either side of the nose), nasolabial folds, upper radial lip lines, lower radial lip lines, lines at the corners of the mouth, marionette lines, perioral lip lines, oral commissures, lip-chin creases, and cobblestone chin.
[0237] To treat the facial wrinkles mentioned above, botulinum toxin is typically administered by intramuscular injection into the following muscles: frontalis (horizontal forehead lines), procerus and corrugator supercilii (glabellar frown lines), lateral orbicularis oculi (crow's feet / periorbital lines), nasalis, transverse procerus nasalis (hare lip lines), levator labii superioris superioris (nasolabial folds), orbicularis oris (upper and lower radial lip lines), depressor anguli oris (corner of mouth lines, marionette lines, oral commissures, lip-mental creases), and mentalis (perioral lip lines, cobblestone chin).
[0238] A further preferred cosmetic use of the liquid preparation according to the invention relates to use in cosmetic applications involving restoration and / or improvement of skin quality on the face and / or body.
[0239] In a seventh aspect, the present invention relates to a method for treating a disease or condition, comprising administering an effective amount of the liquid formulation of the present invention to a person in need thereof.
[0240] The disease or condition may be any of the diseases and conditions mentioned above, whether it is a therapeutic indication or a cosmetic indication. Thus, in one embodiment, the present invention relates to a (non-therapeutic) method for treating a cosmetic (aesthetic) condition, preferably a skin condition, comprising administering an effective amount of a liquid formulation of the present invention to a person in need thereof. In another embodiment, the present invention relates to a (non-therapeutic) method for treating a cosmetic (aesthetic) condition, preferably a skin condition, comprising injecting an effective amount of a liquid formulation of the present invention into a person in need thereof.
[0241] A further preferred method of the present invention relates to a method for restoring and / or improving the quality of facial and / or body skin, comprising administering to a person in need thereof an effective amount of the liquid formulation of the present invention.
[0242] There is no particular limitation on the person to be treated, except for a disease or condition that can be treated according to the present invention. One skilled in the art will be able to determine the appropriate administration regimen for treating a given therapeutic or cosmetic indication. In particular, the injection may be intradermal, subcutaneous or intramuscular, depending on the disease or condition to be treated.
[0243] In addition to the above, the present invention also relates to a method for stabilizing a liquid botulinum toxin formulation, the method comprising mixing a botulinum toxin with human serum albumin (HSA), wherein the HSA is prepared by purifying a human serum albumin starting material to obtain a purified human serum albumin material as described in the fourth aspect of the present invention.
[0244] In addition, the present invention also relates to the use of human serum albumin (HSA) for providing a light- and temperature-stable liquid composition comprising botulinum toxin, wherein HSA is prepared by purifying a human serum albumin starting material to obtain a purified human serum albumin material as described in the fourth aspect of the present invention.
[0245] Example
[0246] I. Examples 1 to 3
[0247] The following examples illustrate liquid botulinum toxin formulations and methods for their preparation according to the present invention. Unless otherwise indicated, percentages are by weight to volume (w / v).
[0248] The biological activity of botulinum toxin was determined using a cell-based potency assay (CBA) as described in WO 2014 / 207109. Briefly, neuronal cells were incubated with a sample containing the neurotoxin and a reference standard of known potency.
[0249] After an incubation period, the cells are lysed and the amount of cleaved SNAP25 protein is determined by immunoassay. The biological activity of the sample is then calculated by comparing the lysis rate of cells treated with the sample to cells treated with a reference standard.
[0250] Example 1
[0251] Photostability and storage stability of liquid botulinum toxin formulations containing HSA (not according to the invention) pretreated by conventional dialysis
[0252] In initial experiments, it was found that the biological activity of a 150 kDa botulinum neurotoxin liquid formulation without complexing proteins (also referred to herein as "150 kDa BoNT / A") was significantly reduced after exposure to light (daylight or room light), and that the photosensitivity increased with increasing concentrations of human serum albumin (HSA). In further experiments, the inventors unexpectedly discovered that the photostability and storage stability of a liquid botulinum toxin formulation at 40°C can be significantly increased by adding a complexing agent such as EDTA, even when EDTA is present in the form of its magnesium, calcium or zinc complexes (results not shown).
[0253] In view of these findings, it was speculated that an unknown component in HSA caused the photosensitivity of botulinum toxin, and that this component could be inactivated or masked by a chelating agent such as EDTA in some way. However, in further experiments conducted by the present inventors, it was surprisingly found that EDTA caused increased injection pain. Therefore, in order to omit chelating agents such as EDTA, the present inventors attempted to remove the unknown component in HSA that caused photoinstability by dialysis.
[0254] To achieve this, a concentrated stock solution of HSA (e.g., 20%) was dialyzed extensively against 10 mM histidine, 0.9% NaCl, pH 6.0 buffer at room temperature for 4×12 hours (three buffer changes, buffer volume approximately 100 times the sample volume) to obtain "dialyzed HSA". The dialyzed HSA and non-dialyzed HSA were then used to prepare the following botulinum toxin (150 kDa BoNT / A, without complexing protein) liquid formulations:
[0255] Formulation 1: 65 U / mL botulinum toxin, 0.1% HSA (not dialyzed), 10 mM histidine, 0.9% NaCl, pH 6.0
[0256] Formulation 2: 65 U / mL botulinum toxin, 0.1% HSA (dialyzed), 10 mM histidine, 0.9% NaCl, pH 6.0
[0257] The photostability of these two formulations was measured at 250 W / m 2 The relative botulinum toxin activity was determined after exposure to light for 7 hours relative to a control sample stored in the dark. 2 The samples were exposed to light for 7 hours using a SUNTEST CPS+ instrument (ATLAS Material Testing Technology LLC) equipped with a filter set to provide a spectral distribution in the wavelength range of 320-800 nm, corresponding to ID65 (indoor indirect daylight standard) of ISO 10977, using a window glass filter according to ICH Q1B. The results are shown in Table 1.
[0258] Table 1 Photostability of liquid botulinum toxin formulations containing undialyzed HSA or dialyzed HSA (7 h, 250 W / m 2 )
[0259]
[0260] As is evident from Table 1, Formulation 2 containing dialyzed HSA had limited effect on photostability compared to Formulation 1 containing non-dialyzed HSA.
[0261] In addition, the storage stability of Formulations 1 and 2 was determined by measuring the relative botulinum toxin activity of the control sample at T0 (measured immediately after preparation of Formulations 1 and 2) after storage at 40°C for 2 weeks and 4 weeks. The results are shown in Table 2. The results are shown in Table 2.
[0262] Table 2 Storage stability of liquid botulinum toxin formulations containing non-dialyzed HSA or dialyzed HSA at 40°C
[0263]
[0264] It can be seen that dialysis has no effect on the storage stability of botulinum toxin.
[0265] Example 2
[0266] Photostability and storage stability of HSA-containing liquid botulinum toxin formulations pretreated with complexing agents and dialysis
[0267] Despite the findings of Example 1 (i.e., EDTA or an EDTA complex is required for photostability; dialyzed HSA does not result in significant improvements in photostability and storage stability), the present inventors continued to investigate liquid botulinum toxin formulations that are photostable and storage stable despite the absence of chelating agents such as EDTA.
[0268] First, EDTA is added to a concentrated stock solution of HSA (e.g., 20%) (100 mM = 37.2 mg Na2-EDTA / ml HSA solution, pH 8.0) and incubated at room temperature for 6 hours with stirring. The incubated mixture is then dialyzed against a buffer containing EDTA (100 mM EDTA, 10 mM histidine, 0.9% NaCl, pH 7.0) at room temperature for 16 hours. The dialysis membrane used is a membrane with a MWCO of 10 kDa and a filling volume of about 0.2 ml / cm 2 Dialysis membrane. The volume of dialysis buffer is about 100 times the volume of the sample.
[0269] Thereafter, the sample was dialyzed for 24 hours at room temperature with a volume of about 100 times the sample volume of EDTA-free dialysis buffer (10 mM histidine, 0.9% NaCl, pH 6.0) to remove EDTA. The dialysis buffer was then replaced with fresh dialysis buffer and dialyzed again for 24 hours. This was repeated twice to obtain pretreated HSA ("EDTA-dialyzed HSA").
[0270] This pretreated HSA was then used to prepare liquid formulation 3 of botulinum toxin (150 kDa BoNT / A, without complexing proteins):
[0271] Formulation 1: Same as Formulation 1 of Example 2 (65 U / mL botulinum toxin, 0.1%
[0272] HSA (not dialyzed), 10 mM histidine, 0.9% NaCl, pH 6.0)
[0273] Formulation 3: 65 U / mL botulinum toxin, 0.085% HSA (EDTA-dialyzed), 10 mM
[0274] Histidine, 0.9% NaCl, pH 6.0
[0275] The photostability of formulations 1 and 3 was measured at 250 W / m 2 The relative botulinum toxin activity was determined after exposure to light for 7 hours relative to a control sample stored in the dark. The results are shown in Table 3.
[0276] Table 3 Photostability of liquid botulinum toxin formulations containing undialyzed HSA or EDTA-dialyzed HSA (7 h, 250 W / m 2 )
[0277]
[0278] As is evident from Table 3, the photostability of Formulation 3 containing EDTA-dialyzed HSA is significantly improved compared to Formulation 1 containing unpretreated HSA.
[0279] In addition, storage stability was determined by measuring the relative botulinum toxin activity of the control sample after storage at 40°C for 2 and 4 weeks relative to that at T0 (measured immediately after preparation of Formulations 1 and 3). The results are shown in Table 4. The results are shown in Table 4.
[0280] Table 4 Storage stability of liquid botulinum toxin formulations containing non-dialyzed HSA or EDTA-dialyzed HSA at 40°C
[0281]
[0282] The results show that the use of EDTA-treated and dialyzed HSA resulted in significantly higher biotoxin activity compared to Formulation 1 containing untreated (non-dialyzed) HSA.
[0283] In summary, this example shows that a chelating agent (e.g., EDTA) can be unexpectedly omitted from a liquid formulation if HSA is pretreated with a chelating agent and then the chelating agent is removed by, for example, dialysis. The resulting formulation is not only stable to light and temperature (storage), but also exhibits reduced injection pain when injected compared to liquid formulations containing chelating agents such as EDTA.
[0284] Example 3
[0285] Effect of iron ions on the photostability of liquid botulinum toxin preparations
[0286] Experiments were also performed to investigate the effect of metal ions on photosensitivity. 2+ ), cobalt (1mMCo2+ ), copper (1mM Cu 2+ ), nickel (1mM Ni 2+ ) or iron (1 mM Fe 3+ ) was added to a liquid formulation containing 50 U / ml 150 kDa BoNT / A, 0.085% pretreated HSA prepared according to Example 2 (i.e., EDTA-treated and dialyzed HSA), 10 mM histidine, 0.9% NaCl, pH 6.0. The liquid formulation was prepared using high-purity water, histidine, and NaCl without using iron or steel equipment. The resulting formulation was exposed to light (at 250 W / m 2 7 hours) and compared with a control formulation stored in the dark.
[0287] It was found that the addition of calcium (1 mM Ca 2+ ) and the addition of cobalt (1 mM Co 2+ ) had no effect on photostability (74% and 77% residual toxin activity compared to the control formulation stored in the dark). Addition of copper (1 mM Cu 2+ ) and nickel (1mM Ni 2+ ) resulted in a relatively small decrease in photostability. In contrast, addition of iron (1 mM Fe 3+ ) resulted in a dramatic decrease in photostability, with exposure to light (250 W / m 2 After 7 hours, only 1% of the residual toxin activity remained.
[0288] In view of these results, the Fe 3+ Effect of ions on the photosensitivity of liquid BoNT / A formulations. Similar to the above experiments, the same formulation containing pretreated HSA (50 U / ml botulinum toxin, 0.085% pretreated HSA, 10 mM histidine, 0.9% NaCl, pH 6.0) was used, and Fe(NO3)3 was added using a stock solution (50 mM Fe(NO3)3). 3+ The concentration was adjusted to the desired final concentration. 2 The bioactivity measured after 7 hours under light is expressed as a percentage of the bioactivity measured for the respective samples stored in the dark, as shown in Table 5.
[0289] Table 5 .Contains pre-treated HSA and different Fe 3+ Light stability of liquid botulinum toxin preparations at different concentrations (7 h, 250 W / m 2 )
[0290]
[0291] As can be seen from Table 4, at a concentration of 316 nM, Fe 3+ The ions had a significant effect on BonT / A stability, with a >15% decrease in stability. At a concentration of 1 μM, the photostability was significantly reduced; however, it was still higher than at concentrations above 1 μM. At 1 μM and higher concentrations, under the influence of light, the added Fe 3+ Ions have a very negative impact on the stability of BoNT / A in liquid formulations.
[0292] In another experiment, it was found that stirring a liquid botulinum toxin formulation containing pretreated HSA (i.e., 50 U / ml botulinum toxin, 0.085% pretreated HSA, 10 mM histidine, 0.9% NaCl, pH 6.0) in a stainless steel beaker for 48 hours resulted in a decrease in the amount of botulinum toxin produced by exposure to light (250 W / m 2 The relative BoNT / A activity after 7 hours of stirring in a polypropylene container was only about 2%, compared to 78% for the same sample stirred in a polypropylene container for 48 hours. This is a very surprising finding, which may be due to the small amount of Fe 3+ ions leached from the stainless steel beaker into the liquid botulinum toxin formulation and indicated that iron ions are an important factor to consider when preparing liquid botulinum toxin formulations.
[0293] II. Examples 4 to 6
[0294] The following Examples 4 to 6 also demonstrate the photostability of the liquid botulinum toxin formulations according to the present invention. To this end, several liquid botulinum toxin formulations were prepared (Example 4), and samples of each of the prepared formulations were exposed to 250 W / m 2 The samples were exposed to light for 7 hours or stored in the dark for 7 hours as a control. The botulinum toxin activity of the samples exposed to light and the samples stored in the dark was then measured by cell-based potency assay (CBA). The photostability was expressed as the percentage of the average botulinum toxin activity of the samples exposed to light to the average botulinum toxin activity of the samples stored in the dark.
[0295] The biological activity of botulinum toxin was determined using a cell-based potency assay (CBA) described in WO 2014 / 207109. Briefly, neuronal cells were incubated with a sample containing the neurotoxin and a reference standard of known potency. After the incubation period, the cells were lysed and the amount of cleaved SNAP25 protein was determined by immunoassay. The biological activity of the sample was then calculated by comparing the division rate of cells treated with the sample and cells treated with the reference standard.
[0296] For 250W / m 2 The samples were exposed to light of 7°C for 7 hours using a SUNTEST CPS+ instrument (ATLAS MaterialTesting Technology LLC) equipped with a filter set to provide a spectral distribution in the wavelength range of 320-800 nm, corresponding to ID65 (indoor indirect daylight standard) of ISO 10977, using a window glass filter according to ICH Q1B.
[0297] Example 4
[0298] Preparation of different botulinum toxin preparations
[0299] The compositions of the formulations to be analyzed for photostability are shown in Tables 6 and 7. The botulinum toxin (BoNT) used was NT101.
[0300] Table 6 .Test formulations containing untreated / pretreated HSA
[0301]
[0302]
[0303] Table 7 .Test formulations containing tryptophan (Trp) / N-acetyl-tryptophan (N-AcTrp)
[0304]
[0305]
[0306] Preparation of "dialyzed HSA" . Transfer 10 ml of 25% HSA (CSL Behring) into a dialysis cassette (Slide-A-Lyzer TM , 10kDa MWCO, 12-30ml, Thermo Scientific / Pierce). The dialysis cassette was placed in 2 liters of solution (1.55g / L histidine, 9g / L NaCl, pH 6.0) and dialyzed for 24 hours in dark and stirring (150rpm, magnetic stirrer). Subsequently, the dialysis buffer was replaced with 2 liters of fresh dialysis buffer (1.55g / L histidine, 9g / L NaCl, pH 6.0), and the process was repeated three times or more, each time for about 12 hours. The final contents of the dialysis cassette are referred to as dialyzed HSA or "HSA dialysate". The concentration is determined as described below.
[0307] Preparation of "dialyzed HSA-EDTA"18 ml of 25% HSA (CSL Behring) was mixed with 2 ml of 1 M Na2EDTA (pH 8.0). The resulting solution was stirred for about 6 hours. Then, about 15 mL of the solution was transferred to a dialysis cassette (Slide-A-Lyzer TM , 10 kDa MWCO, 12-30 mL, Thermo Scientific / Pierce). The dialysis cassette was placed in 2 liters of a solution (1.55 g / L histidine, 9 g / L NaCl, 37.2 g / L Na2EDTA, pH 7.0) and dialyzed for 24 hours in a dark environment with stirring (150 rpm, magnetic stirrer).
[0308] Next, the dialysis buffer was replaced with 2 liters of 1.55 g / l histidine, 9 g / l NaCl, pH 7.0, followed by dialysis for about 12 hours, with the dialysis buffer replaced with 2 liters of fresh dialysis buffer (the first buffer was replaced with His / NaCl, pH 6.5, and the second and third buffers were replaced with His / NaCl, pH 6.0). The final contents of the dialysis cassette were EDTA-dialyzed HSA material (or "HSA-EDTA dialysate").
[0309] Due to the volume increase during the dialysis process, the HSA concentration after dialysis is usually significantly lower than the concentration of the starting HSA solution (25% w / v). Due to the high protein concentration, no significant loss is expected, the absolute amount of HSA is considered unchanged, and the concentration is calculated based on the volume change known to the skilled person. The HSA concentration after dialysis was determined to be about 8.1% w / v.
[0310] Preparation of placebo stock solution To prepare the formulations shown in Tables 6 and 7 but without active agent (BoNT) (referred to herein as "placebo stock"), the starting materials HSA, NaCl and histidine were weighed and dissolved in water (Milli-Q). 50 mM stock solutions of tryptophan (Trp) and N-acetyl-tryptophan (N-AcTrp) were prepared (10.212 g / l and 12.313 g / l, respectively, in warm water) and dosed according to the desired final Trp and N-AcTrp concentrations. Finally, the pH was adjusted to 6.0 by adding 1 M NaOH or 1 M HCl, made up to the final volume with water, and the solution was sterile filtered through a 0.22 μm filter.
[0311] Preparation of BoNT pre-dilution 13.44 mg of NT101 was weighed into a 50 mL sterile low protein binding tube and mixed with 20.123 g of sterile filtered placebo stock of Formulation 7 to obtain a pre-dilution containing 25,000 U / ml BoNT.
[0312] Sample preparation . 20.0 μl of BoNT pre-dilution was placed in a sterile 15 ml low protein binding tube and 9.98 ml of the corresponding placebo stock solution was added. The solution was gently inverted 10 times to mix. Then, 3 × 1 ml of each solution was placed in a 1.5 ml low binding tube and exposed to 250 W / m 2 The remainder of each sample solution was covered with aluminum foil and stored in batches at 4°C until measurement ("dark control" samples).
[0313] Example 5
[0314] Comparison of photostability of different liquid BoNT formulations
[0315] The botulinum toxin activity of samples of Formulations I to IV in Table 6 was measured using CBA (multiple measurements) and the samples were exposed to 250 W / m 2 The samples were exposed to light for 7 hours or stored in the dark for 7 hours. The results shown in Table 8 are the percentage of activity of the samples exposed to light relative to the control samples stored in the dark.
[0316] Table 8 Comparison of photostability of different liquid BoNT formulations
[0317]
[0318]
[0319] As can be seen in Table 8, dialysis of HSA increases the stability of BoNT to light exposure to some extent (see Formulation II vs. Formulation I). Addition of EDTA to untreated HSA has a significantly greater positive effect (see Formulation III). However, addition of EDTA does not completely prevent the destabilizing effects of light. The best photostability is achieved by pre-incubation with EDTA followed by dialysis against histidine buffer without EDTA (see Formulation IV). This suggests that the observed photostability may not be solely due to metal ions but to other unknown compounds.
[0320] Example 6
[0321] Photostability of liquid BoNT formulations in the presence and absence of tryptophan and N-acetyl-tryptophan
[0322] The botulinum toxin activity of samples of Formulations 1 to 7 in Table 7 was measured using CBA (multiple measurements) and the samples were exposed to 250 W / m 2 The results shown in Table 9 are the percentage activity of the samples exposed to light relative to the control samples stored in the dark.
[0323] Table 9 Comparison of photostability of liquid BoNT formulations in the presence or absence of tryptophan or N-acetyl-tryptophan
[0324]
[0325]
[0326] As can be seen, both tryptophan and N-acetyl-tryptophan had a significant negative effect on the photostability of the BoNT liquid formulations in a dose-dependent manner. At higher concentrations (10 mM and 2 mM, respectively), the photostability-reducing effect was so pronounced that the relative bioactivity was extremely low (<10%). At concentrations as low as 80 μM of Trp or N-AcTrp, BoNT bioactivity was reduced by approximately 10% after exposure to light compared to control formulations without Trp and N-AcTrp (see Formulations 4 and 6 vs. Formulation 7).
[0327] The concentration of 80 μM N-acetyl-tryptophan corresponds to diluting 25% w / v HSA starting material (containing 20 mM N-AcTrp) to 0.1% w / v or 1 mg / ml HSA. Since the value of 1 mg / ml HSA falls within the concentration range typically used in botulinum toxin formulations, the use of this HSA starting material results in N-acetyl-tryptophan concentrations in BoNT / A formulations with increased photosensitivity. Therefore, the concentration range in which tryptophan and N-acetyl-tryptophan negatively affect photostability has important practical implications.
Claims
1. A liquid preparation comprising (i) Botulinum toxin and (ii) human serum albumin, The liquid preparation contains Fe at a concentration of less than 1 μM, preferably less than 500 nM, and more preferably less than 250 nM. 3+ ion.
2. A liquid preparation comprising (i) Botulinum toxin and (ii) human serum albumin, The liquid preparation contains no or no more than 50 μM tryptophan and N-acetyl-tryptophan.
3. A liquid preparation comprising (i) Botulinum toxin and (ii) human serum albumin, Wherein the liquid preparation is prepared by a method comprising the following steps: (a) contacting human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and (b) removing the chelating agent from the mixture.
4. The liquid preparation according to claim 1, wherein the liquid preparation is prepared by a method comprising the following steps: (a) contacting human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and (b) removing the chelating agent from the mixture.
5. The liquid preparation according to claim 3 or 4, wherein In step (a), a human serum albumin starting material is contacted with a chelating agent to obtain a mixture of said human serum albumin starting material and the chelating agent, and in step (b), said chelating agent is removed from the mixture to obtain a pretreated human serum albumin material, and in a further step (c), a botulinum toxin is mixed with said pretreated human serum albumin material, wherein said chelating agent is preferably removed by dialysis, filtration, cross-flow filtration or ultrafiltration, or wherein in step (a), a liquid preformulation comprising botulinum toxin and human serum albumin is contacted with a chelating agent to obtain a mixture of the liquid preformulation and the chelating agent, and in step (b), the chelating agent is removed from the mixture to obtain a liquid preparation, wherein the chelating agent is preferably removed by dialysis, filtration, cross-flow filtration or ultrafiltration.
6. The liquid preparation according to any one of claims 1 to 5, wherein the human serum albumin is present in the liquid preparation in an amount of 0.001 to 1.00% w / v.
7. The liquid preparation according to claim 2, wherein the liquid preparation comprises Fe at a concentration of less than 1000 nM, preferably less than 500 nM, more preferably less than 250 nM. 3+ ion.
8. The liquid preparation according to any one of claims 1-7, wherein the liquid preparation further comprises: (iii) tonicity agents, Or wherein the liquid preparation further comprises: (iii) a tonicity agent, wherein the tonicity agent is present in the liquid formulation in an amount of 0.01-2.0% w / v, Alternatively, wherein the tonicity agent is sodium chloride, or wherein the tonicity agent is sodium chloride and is present in the liquid formulation in an amount of 0.01-2.0% w / v.
9. The liquid preparation according to any one of claims 1-8, wherein the liquid preparation further comprises: (iv) a buffer, Or wherein the liquid preparation further comprises: (iv) a buffer, wherein the buffer is present in the liquid formulation at a concentration of 1-100 mM, or wherein the buffer is an amino acid, a phosphate or a mixture thereof, or wherein the buffer is histidine, or wherein the buffer is histidine, phosphate or a mixture thereof, and the histidine and phosphate are present in the liquid formulation at a concentration of 1-100 mM.
10. A method for preparing a liquid formulation according to claim 2 or 7, or any one of claims 8 and 9 when dependent on claim 2, wherein the method comprises the following steps: - purifying the human serum albumin starting material to obtain a purified human serum albumin material, - mixing the obtained purified human serum albumin with botulinum toxin and optionally other components to obtain a liquid preparation, or - purifying a liquid composition comprising botulinum toxin and human serum albumin to obtain a purified liquid composition, - mixing the obtained purified liquid composition with other components to obtain a liquid preparation, wherein the purification step is preferably carried out by subjecting the human serum albumin starting material or the liquid composition comprising botulinum toxin and human serum albumin to dialysis, diafiltration, ultrafiltration, ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, field flow fractionation or precipitation (e.g., salt precipitation, ethanol precipitation).
11. The method according to claim 10, wherein the purification step is performed as follows, or wherein the purification step further comprises the following steps: - contacting a human serum albumin starting material with a chelating agent to obtain a mixture of the human serum albumin starting material and the chelating agent, and - removing the chelating agent from the mixture to obtain a chelating agent-treated purified human serum albumin material, or - contacting a liquid composition comprising botulinum toxin and human serum albumin with a chelating agent to obtain a mixture of the liquid composition and the chelating agent, and - removing the chelating agent from the mixture to obtain a chelating agent-treated purified liquid preparation, wherein the contacting steps in methods (i) and (ii) are preferably performed in a manner such that the concentration of the chelating agent in the mixture is 1 mM to 500 mM, and / or the removal of the chelating agent is performed by dialysis, cross-flow filtration or ultrafiltration.
12. The liquid formulation according to any one of claims 3 to 6, 8 and 9 or the method according to claim 10 or 11, wherein the chelating agent is selected from the group consisting of aminopolycarboxylic acids having three to six carboxylic acid functional groups, citrates, porphyrins, N,N,N′,N′-tetrakis(2-pyridylmethyl)-1,2-ethylenediamine (TPEN), triethylenetetramine (TETA) and mixtures thereof. Preferably, the chelating agent is an aminopolycarboxylic acid of general formula (I): (HO2CCH2)2N-RN(CH2CO2H)2(I), Wherein R does not contain a carboxylic acid group or contains one or two carboxylic acid groups, the aminopolycarboxylic acid is preferably selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(b-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), diethylenetriaminepentaacetic acid (DTPA), triethylenetetraaminehexaacetic acid (TTHA) and mixtures thereof.
13. The liquid formulation of any one of claims 1-9 and 12 or the method of claim 10 or 11, wherein the botulinum toxin is a botulinum neurotoxin complex, or wherein the botulinum toxin is a botulinum neurotoxin without complexing proteins, or wherein the botulinum toxin is a botulinum neurotoxin of serotype A, or wherein the botulinum toxin is a botulinum neurotoxin of serotype A without complexing proteins, or wherein the botulinum toxin is a botulinum neurotoxin of serotype A and is present at a concentration of 1-1000 U / ml, or wherein the botulinum toxin is a botulinum neurotoxin of serotype A without complexing proteins and is present at a concentration of 1-1000 U / ml, or wherein the pH of the liquid formulation is in the range of 5.0-8.
0.
14. The liquid formulation according to any one of claims 1 to 9, 12 and 13 for use in therapy, in particular for the treatment of neuromuscular diseases, pain, salivation, hyperhidrosis, urinary system disorders and nervous system disorders.
15. Cosmetic use of a liquid formulation according to any one of claims 1 to 9, 12 and 13 for the treatment of cosmetic conditions.
